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Glial cell-line derived neurotrophic factor (GDNF) is a potent neurotrophic factor which 
shows restorative effects in a wide variety of rodent and primate models of Parkinson’s 
disease (PD). It promotes the survival of a broad range of central and peripheral neurons 
and is essential for kidney and enteric nervous system development, as well as regulating 
the fate of stem cells during spermatogenesis. GDNF binds preferentially to GDNF family 
receptor alpha 1 (GFRα1), which mediates the activation of the proto-oncogene c-Ret 
receptor protein-tyrosine kinase to form a multi-component system and trigger off 
downstream signaling events. Two alternatively spliced GFRα1 isoforms, GFRα1a and 
GFRα1b have been previously identified. GFRα1a and GFRα1b are highly homologous, 
with GFRα1a containing an extra 15 nucleotide (exon 5) compared to GFRα1b. Currently, 
the specific physiological functional roles of GFRα1a and GFRα1b are unknown. Further 
more, the distribution and expression levels of these two isoforms have not been reported. 
To understand the physiological and functional role of GFRα1a and GFRα1b, stably 
transfected cell lines containing endogenous c-Ret were established to generate cells over-
expressing either GFRα1a or GFRα1b. Using the cell lines, mechanisms involved in the 
signaling pathways and functional roles of GFRα1a and GFRα1b in cell morphological 
differentiation and proliferation were investigated. An isoform specific quantitative real-
time PCR was used to confirm the existence and to measure the transcriptional expression 
levels of GFRα1a and GFRα1b in various human tissues.  
 viii
The signaling pathway studies showed that cells expressing GFRα1a or GFRα1b when 
stimulated by specific GDNF family ligands (GFL), GDNF and Neurturin (NTN), resulted 
in rapid activation of MAPK (Erk1/2) and significantly different morphological changes. 
A modurate but significant difference in the kinetics of the phosphorylation of Erk1/2 was 
detected when GFRα1a and GFRα1b transfected cells were exposed to NTN. No 
significant changes in the proliferation profile in the transfected cells were observed 
compared to parental cells containing the vector only. Real time PCR revealed that both 
GFRα1a and GFRα1b isoforms existed in all the human tissues examined, and the 
transcriptional expression levels of the two isoforms were similar in human fetal and adult 
brain. GFRα1b levels were found to be much higher than GFRα1a in peripheral tissues. 
In conclusion, the two spliced isoforms, GFRα1a and GFRα1b are differentially expressed 
in the human tissues examined. A close investigation reveals that the both isoforms, 
despite having only 5 amino acid sequence difference, show remarkable differences in 
their signaling and capabilities in inducing morphological differentiation. 
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Neurotrophic factors play crucial roles in the development, growth and maintenance of the 
developing and adult nervous systems. They are secreted polypeptides, regulating many 
aspects of neuronal and glial structures and functions via paracrine and autocrine 
mechanisms (Yuen and Mobley 1996).  
Since the discovery of the first neurotrophic factor, Nerve growth factor (NGF) (Bradshaw 
et al. 1993), many other neurotrophic factors have been since identified and characterized 
based on either their structural or functional similarities. These neurotrophic factors 
include neurotrophins, neurokines and the glial cell line-derived neurotrophic (GDNF) 
family of ligands. All these neurotrophic factors signal via specific multi-component 
receptor complexes (Siegel and Chauhan 2000).  
In the vertebrate nervous system, ample evidence suggest that neurotrophic factors play 
critical roles in the survival and phenotypic differentiation of developing neurons and the 
maintenance and protection of mature and injured neurons (Ebadi et al. 1997; Connor and 
Dragunow 1998). Alteration in neurotrophic factor levels due either to age, genetic 
background or other factors might contribute to neuronal degenerations characteristic of 
Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases 
(Miyazaki et al. 2003). Some recent therapeutic strategies have included the use of 
neurotrophic factors in preventing, reducing and rescuing the neuronal loss and atrophy 
that occur in neurodegenerative disorders such as AD and PD (Martin et al. 1995; Martin 
et al. 1996; Bjorklund et al. 1997; Kordower et al. 2000; Tuszynski et al. 2002).  
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1.2 GDNF in Parkinson’s disease (PD) 
PD is a common progressive neurodegenerative disease which affects almost 1 % of the 
worldwide population over 65 (Giasson and Lee 2000). It is caused by degeneration of 
neurons in a region of the brain that controls movement. PD is characterized by selective 
degeneration of substantia nigra dopaminergic neurons and was first described by a 
London physician James Parkinson in 1817. This neuronal degeneration creates a shortage 
of the brain signaling chemical, dopamine, which in turn leads to impaired motor function. 
PD is characterized clinically by rigidity, tremor and bradykinesia, which result from the 
progressive death of dopaminergic neurons in substantia nigra region in the brain. The 
defining feature of classical PD is the accumulation of Lewy bodies revealed in 
microscopic observation of brain sections, which contain ubiquitin and α-synuclein (Baba 
et al. 1998). Although the symptoms and pathology of PD have been well characterized, 
the underlying mechanisms and the cause of the disease still remained unknown. 
A number of studies have shown the potential of GDNF as a therapeutic agent for 
neurodegenerative diseases like PD. Injection of GDNF into the substantia nigra or 
striatum potently protected dopaminergic system and significantly restored the dopamine 
levels and dopaminergic fiber densities after the administration of MPTP,(1-methyl-4 
phenyl-1,2,3,6 - tetrahyropyridine), a neurotoxin known to cause Parkinsonian-like 
symptoms, in experimental animals (Opacka-Juffry et al. 1995; Tomac et al. 1995; Shults 
et al. 1996; Gash et al. 1998). GDNF has also been shown to promote the differentiation 
and survival of mesencephalic substantia nigral dopaminergic neurons both in vitro and in 
vivo and enhances their dopamine up-take (Hudson and A.C Granholm 1993; Lile et al. 
1993; Stromberg et al. 1993; Bowenkamp et al. 1995; Gash et al. 1995; Krieglstein et al. 
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1995; Heller et al. 1996; Connor et al. 2001). In various experimental PD models, the 
level of GDNF in the substantial nigra was found to decrease prior to the onset of 
symptoms, which may be indicative of early symptom resulting from selective neuronal 
degeneration in this region (Meyer et al. 1999; Oo et al. 2003). These studies are 
suggestive of a potential therapeutic role of GDNF in the treatment of PD (Lile et al. 1993; 
Schaar et al. 1993; Schmidt-Kastner et al. 1994; Gash et al. 1995; Opacka-Juffry et al. 
1995; Martin et al. 1996; Shults et al. 1996). Further studies have demonstrated a 
neurochemical and behavioral improvement in unilateral dopamine-lesioned animal 
models after intranigral administration of GDNF. This suggests that GDNF maintains 
dopaminergic neuronal phenotype survival after a nigrostriatal lesioning in the rat brain. 
This is consistent with a possible physiological role of GDNF in regulating the event. The 
most recent in vivo study involving direct administration of GDNF into striatal target 
demonstrated a role for this neurotrophic factor in preventing the early phase of neuronal  
death by suppressing apoptosis in dopaminergic neurons (Oo et al. 2003). The recent 
success of the clinic phase 1 trial of GDNF for the treatment for Parkinson patients has 
lend further evidence that GDNF is a promising therapeutic agent  (Gill et al. 2003).  
Despite the many studies of the physiological significance of GDNF, the biochemical and 
molecular mechanisms underlying its neuroprotective effects are only beginning to be 
unraveled. 
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1.3 GDNF family 
1.3.1 GDNF family ligands (GFLs) 
The GDNF family of growth factors consists of four members, glial cell line-derived 
neurotrophic factor (GDNF), neurturin (NTN), persephin (PSP) and artemin (ART). They 
are structurally related homologous proteins and belong to a subfamily of growth factors 
within the transforming growth factor-β (TGF-β) superfamily. GDNF was first isolated 
from B49 rat glial cells, and was shown to have a potent neurotrophic effects in cultured 
rat embryonic dopaminergic neurons (Lin et al. 1993). NTN was purified as a survival 
factor for sympathetic neurons (Kotzbauer et al. 1996). ART and PSP were then 
identified based on their sequence homology to GDNF and NTN (Baloh et al. 1998; 
Milbrandt et al. 1998). NTN and ART have many neurotrophic effects that are similar to 
GDNF. In contrast, PSP is expressed at low level in most tissues and supports CNS 
dopamine and motor neurons survival, but not peripheral neurons (Milbrandt et al. 1998). 
All the four members exert their neurotrophic effects through a multi-component receptor 
signaling system formed by the interactions between the Ret tyrosine kinase (Takahashi 
et al. 1985) and a cysteine-rich GPI-anchored specific binding subunit called GDNF 
family receptor alpha (GFRα) (Fig.1.1). Recently, this multi-component signaling 
complex is shown to include the neural cell adhesion molecule (NCAM) 
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Fig 1.1 GDNF family ligands and their preferential receptors signal through the Ret receptor tyrosine 
kinase. 
Homodimeric GDNF family ligands activate the transmembrane Ret tyrosine kinase receptor via the 
GPI-linked GFRα receptor. Thick lines indicate the preferred functional interaction, whereas dotted 












Fig.1.2 NCAM as an alternative receptor for GDNF signaling receptor complex 
GDNF signals through the interacting with GFRα1and NCAM complex, which leads to activation of 
Fyn tyrosine kinase. It is currently unknown if other GDNF family of ligands signal in the same 






1.3.2 GDNF family receptors  
Until recently, GFLs were thought to signal through a receptor complex comprising of a 
high-affinity binding receptor (GFRα1 - GFRα4) and a common component, Ret. All the 
four members of GFLs have their own preferred receptors (Fig.1.1). GDNF signals 
preferentially via GFRα1 (Jing et al. 1996; Treanor et al. 1996), NTN via GFRα2 (Baloh 
et al. 1997; Jing et al. 1997; Klein et al. 1997), while ART signals through GFRα3 (Jing et 
al. 1997; Baloh et al. 1998), and GFRα4 (Thompson et al. 1998) is the receptor for PSP. 
NTN can also stimulate GFRα1 almost equally as well as GDNF in cell lines (Baloh et al. 
1997; Creedon et al. 1997; Jing et al. 1997), whereas ART and GDNF only interact 
weakly to GFRα1 and GFRα2, respectively (Baloh et al. 1997; Jing et al. 1997; Baloh et al. 
1998). High concentrations of NTN can also mediate responses through the activation of 
GFRα4 (Enokido et al. 1998). 
GFRα receptors are plasma membrane proteins attached to the membrane by a glycosyl 
phosphatidylinositol (GPI) anchor. The amino acid sequences of GFRα1 and GFRα2 have 
revealed internal homologies within a conserved cysteine-rich domain and suggests a 
common domain structure shared by the two receptors (Suvanto et al. 1997). A similar 
domain is also present in GFRα3 and GFRα4.  
 
1.3.3 c-Ret as co-receptor for GDNF family  
As the specific GFRα receptor of GDNF is a GPI linked membrane surface protein, it was 
thought that the GFRα may require the interaction with another transmembrane spanning 
receptor for intracellular signaling. c-Ret was subsequently identified as the second 
signaling so-receptor GDNF as c-Ret was shown to co-immunoprecipitate with 
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GDNF/GFRα and is functionally involved in mediating the biological responses of GDNF 
(Durbec et al. 1996; Trupp et al. 1996). 
In human, activating germline Ret mutations are associated with inherited cancer 
syndrome known as multiple endocrine neoplasia type 2A and 2B (MEN2A, MEN2B), 
familial medullary thyroid carcinoma (FMTC) and papillary thyroid carcinomas (PTC) 
(Santoro et al. 1995; Eng et al. 1996; Edery et al. 1997). On the other hands, the lose of 
function of Ret causes Hirschsprung’s disease, a congenital disorder of the enteric nervous 
system. 
Ret was originally identified and described as a novel oncogene in 1985 (Takahashi et al. 
1985). The Ret gene encodes a single-pass transmembrane receptor tyrosine kinase with 
four cadherine-like repeats in its extracellular domain and an intracellular tyrosine kinase 
domain. The intracellular domain of Ret consists of 14 tyrosine residues (a short isoform 
of Ret lacks 2 tyrosine residues at the c-terminus). Phosphorylated tyrosine residues were 
identified as docking sites adaptor proteins such as Grb10, Grb7, Shc and Src (Pandey et 
al. 1995; Asai et al. 1996; Pandey et al. 1996; Airaksinen et al. 1999; Encinas et al. 2004). 
The Ret gene was mapped to human chromosome 10q11.2 (Ishizaka et al. 1989), with a 
total of 21 exons and multiple alternative spliced isoforms (Myers et al. 1995).   
 
1.3.4 GDNF family multi-component receptor complex signaling  
GFLs bind to specific GFRα receptors, which leads to the activation of Ret by tyrosine 
autophosphorylation. In the original model, a GDNF molecule as a homodimer first binds 
to the two monomeric GFRα1, and the GDNF-GFRα1 complex then interacts with Ret, 
promoting Ret dimerization and autophosphorylation (Jing et al. 1996). Ret has been 
 9
shown to activate several pathways when the tyrosine autophosphorylation occurs. This 
includes the Ras-MAPK (Santoro et al. 1994; Worby et al. 1996), phosphatidylinositol 3-
kinaes (PI3K) (van Weering and Bos 1997), Jun N-terminal kinase (JNK) (Chiariello et al. 
1998; Xing et al. 1998) and PLCγ (Borrello et al. 1996) dependent pathways.  
The stoichiometry and kinetics of the multicomponent ligand-receptor complex are not 
well understood. GPI linked membrane receptors were thought to cluster into lipid rafts to 
form a signaling patch, which is essential for the recruitment of  Ret to the lipid raft after 
GDNF stimulation, resulting in Ret/Src association (Tansey et al. 2000). It is assumed that 
the other GFL members bind to their specific receptor and activate Ret in a similar manner. 
GFRα receptors utilize transmembrane Ret as a signaling co-receptor upon the 
stimulations of the GDNF family ligands. However, in the absence of Ret, GDNF family 
ligands can still signal in some cells which expresses GFRα receptor, indicating the 
involvement of a possible new member of co-receptor (Poteryaev et al. 1999; Trupp et al. 
1999). The most recent report of the neural cell adhesion molecule, NCAM as an 
alternative signaling receptor for GDNF family ligands proves the existence of a Ret 
independent signaling pathway. NCAM can associates with GFRα1 and promotes high-
affinity binding of GDNF and NCAM, resulting in rapid activation of cytoplasmic protein 
tyrosine kinases Fyn and FAK in cells lacking Ret (Paratcha et al. 2003). 
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1.4 GDNF  
1.4.1 Discovery and identification of  GDNF  
GDNF is the first member of the GDNF family discovered. It was initially isolated and 
cloned as a factor produced by B49 rat glial cells with potent neurotrophic effects in 
cultured embryonic rat midbrain dopaminergic neurons (Lin et al. 1993; Lin et al. 1994). 
GDNF is a glycosylated, disulfide-bonded homodimer with a molecular weight of 
approximately 33-45 kDa. Analyses of the sequence of GDNF isolated from B49 rat glial 
cells suggests that GDNF is secreted as a mature protein of 134 amino acids (Lin et al. 
1993). Its amino acids sequence revealed that it is closely related to transforming growth 
factor beta (TGF-β) superfamily, containing seven cysteine residuals, but shared less than 
20% of overall sequence homology as compared to TGF- β (Milbrandt et al. 1998). The 
potential receptor binding surfaces have been identified based on the crystal structure of 
GDNF (Eigenbrot and Gerber 1997). In human, the gene coding for GDNF is located on 
chromosome 5p12-p13.1 (Schindelhauer et al. 1995). 
 
1.4.2 Neurotrophic effects of GDNF 
GDNF is a potent neurotrophic factor which promotes the survival of a wide variety of 
neurons, including dopaminergic, motor, noradrenergic, enteric, parasympathetic, 
sympathetic and sensory neurons (Henderson et al. 1994; Airaksinen et al. 1999; Manie et 
al. 2001; Airaksinen and Saarma 2002). It is also essential for ureteric branching in kidney 
formation (Towers et al. 1998; Sariola and Saarma 1999) and regulates the fate of stem 
cells during spermatogenesis (Meng et al. 2000). GDNF is now known to promote the 
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survival neuronal populations in both the central and peripheral nervous systems (Baloh et 
al. 2000; Takahashi 2001) and has important functions both in neuronal and non-neuronal 
tissues (Sariola 2001). In vitro, GDNF supports the survival of embryonic, dopaminergic 
neurons (Lin et al. 1993), increases potently the survival of embryonic rat motor neurons 
in culture by increasing cell number, neurite outgrowth, choline acetyltransferase activity 
(Henderson et al. 1994; Zurn et al. 1996) and promotes regeneration and protection of 
injured neurons (Bennett et al. 1998). In vivo, GDNF almost completely rescues motor 
neurons in rats from lesion-induced cell death (Yan et al. 1995; Rosenblad et al. 1999). In 
gene knockout model of GDNF-/-mouse, a subset of spinal motor neurons as well as 
neurons in superior cervical ganglion, dorsal root ganglion and NPG (Baloh et al. 2000) 
were missing, indicating that those neurons require GDNF for survival.  
GDNF exerts its neurotrophic effect via a multi-component signaling system. In vivo, 
GDNF is thought to be released in limited amounts by distinct target tissues in which it 
binds to its specific receptors and activate Ret. Using PCR techniques, the regional 
distribution and cellular localization of GDNF has been examined in the human and 
mouse CNS (Schaar et al. 1993; Stromberg et al. 1993; Schaar et al. 1994; Springer et al. 
1994). In human CNS, GDNF transcripts have been identified in the striatum, caudate, 
hippocampus, cortex and spinal cord. Similarly, in the rat CNS, GDNF is expressed in all 




1.5.1 GFRα1 and its spliced isoforms  
GFRα1 is an essential component of the multi-component receptor complex in GDNF 
signaling. It also responds to the stimulation of NTN and mediates its signaling 
transduction. GFRα1 was discovered by expression cloning and screening of GDNF 
binding protein. From the studies, a cDNA clone of GFRα1 from mouse retinal culture 
was identified to encode a polypeptide of 486 amino acids (Jing et al. 1996; Treanor et al. 
1996). GFRα1 is a GPI (glycosyl phosphatidylinositol) linked cell surface protein, binds 
GDNF with high affinity and mediates the association of GDNF with Ret. GFRα1 is rich 
in cysteine (31 of 468 amino acids) and has a N-terminal hydrophobic domain with the 
characteristics of a secretory signal peptide and a C-terminal hydrophobic region of about 
20 amino acids in length. The human GFRα1 was isolated by cross-species hybridization 
screening using rat cDNA and a cDNA library prepared from adult human substantial 
nigra. The human GFRα1 is a polypeptide of 465 amino acids and is 93% identical to 
mouse GFRα1. The human GFRα1 gene locus spans a genomic region of around 70 kb 
and is located at chromosome 10q25. The gene is encoded by 11 exons, which includes an 
untranslated exon upstream of the first methionine and 10 additional exons (Eng et al. 
1998). 
Two alternative spliced transcripts of GFRα1, GFRα1a (Jing et al. 1996; Treanor et al. 
1996) and GFRα1b (Jing et al. 1996; Treanor et al. 1996; Dey et al. 1998) were identified. 
Both isoforms are highly homologous except that GFRα1b lacks exon 5 (5 amino acids) 
compared to GFRα1a. Currently, the functional and physiological roles of the two spliced 
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isoforms are unknown and remain to be elucidated. Furthermore, the tissue distribution 
and expression levels of these two isoforms have not been reported.  
 
1.5.2 Expression and functional role of GFRα1a  
Since GFRα1 was originally discovered and described as GPI-linked protein required by 
GDNF for its physiological responses (Jing et al. 1996; Treanor et al. 1996), the 
expression and functional role of GFRα1 as receptor for neurotrophic factor GDNF have 
been widely reported. In vivo, GFRα1 is coexpressed with Ret in the developing kidney 
and enteric system. GFRα1 deficient mice have deficits in the enteric nervous system and 
kidneys (Cacalano et al. 1998; Enomoto et al. 1998). GFRα1 is widely expressed in a 
number of GDNF-responsive neuronal populations, including midbrain dopaminergic and 
spinal cord motor neurons (Garces et al. 2000; Marco et al. 2002). It has also been 
detected in peripheral ganglia, including the trigeminal, nodose, superior cervical and 
dorsal root ganglia (Trupp et al. 1997; Cacalano et al. 1998; Widenfalk et al. 1999). In 
human, the abnormal expression of GFRα1 has been associated with Hirschsprung’s 
disease and sporadic modular thyroid carcinoma (Gimm et al. 2001; Lui et al. 2002). 
Expression of GFRα1 has been detected in human developing and adult spinal cord, dorsal 
root ganglia and testis during fetal development and in adult men (Davidoff et al. 2001), 
suggesting a critical role for GDNF and GFRα1during the differentiation of testicular 
structure. A recent report of soluble and bound forms of GFRα1 eliciting different GDNF-
independent neurite growth responses indicates that GFRα1 may signal without GDNF 
and plays additional physiological roles other than being the receptor for GDNF (Mikaels-
Edman et al. 2003). 
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1.6 Alternatively spliced isoforms 
Alternative splicing is a mechanism, by which more than one transcript (mRNA) can be 
expressed form a single gene locus (Gilbert 1978). This increases the information 
contained within one gene and allows complexity in the regulation of its expressions. It 
was estimated that 5 % of genes in higher eukaryotes have alternative spliced forms 
(Sharp 1994). The completed human genome revealed a number of human expressed 
mRNA that is much higher than the number of genes (30,000 – 40,000 human genes), 
suggesting a major role for alternative splicing in the production of genetic complexity 
(Modrek and Lee 2002).  
Various alternative spliced isoforms of different growth factor receptors have been 
reported, examples of these are FGFR1, TrkA, TrkB, TrkC (Barbacid 1994; Wang et al. 
1995; Tam et al. 1997),VEGF receptors (Giasson and Lee 2000), GFRα2 (Wong and Too 
1998) and GFRα4 (Lindahl et al. 2000). Spliced variants of Ret have been demonstrated 
to have distinct biochemical and physiological functions (Giasson and Lee 2000). The 
alternative spliced forms of the receptors showed differences in specificities and affinities 
to the cognate ligands as well as their signaling pathways. Characterization of NGF (Selby 
et al. 1987) in rat, mouse and human have shown that several different transcripts are 
produced from as many as four exons found upstream of the coding region. In the case of 
the BDNF gene, alternative splicing give rise to 6 different transcripts (Nakayama et al. 
1994). The tissue specific expressions of the isoform provide evidence that alternative 
splicing of the BDNF gene produced proteins of different biological significance. Hence, 
the existence of spliced isoforms and their differential distributions may influence the 
physiological responses profoundly. 
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1.7 Quantification of gene expression  
1.7.1 Quantification of gene expression at transcription level 
Determination of the expressions of the alternatively spliced variants of a gene is 
increasingly important as many cellular decision involving survival, growth and 
differentiation are reflected in the quantitative differential expressions of these variants 
(Zamorano et al. 1996). Four methods are commonly used for the quantification of 
transcription. These include Northern blotting, RNA in situ hybridization (Parker and 
Barnes 1999), RNAse protection assays (Hod 1992) and reverse transcription polymerase 
chain reaction methods (RT-PCR) (Weis et al. 1992). Northern blotting is the only method 
that provides information about the mRNA size, alternative spliced transcripts and the 
integrity of the sample. The RNase protection method is most useful for mapping the 
initiation and termination sites and intron/exon boundaries of transcripts. RNA In situ 
hybridization allows the localization of transcripts to specific cellular location within a 
tissue. These three methods have a low sensitivity compared to RT-PCR (Melton et al. 
1984). RT-PCR is an in vitro method that involves enzymatical amplification of target 
sequence of mRNA (Rappolee et al. 1988). All these methods have their own limitations. 
Northern blotting is time-consuming and requires relatively large amounts of RNA. RNase 
protection analysis is more sensitive than Northern blotting, but it is not sensitive enough 
to detect low abundance transcripts. To quantify gene expressions using RT-PCR, the 
reaction must be terminated and quantified in the early exponential phase, which is often 
not easily controlled (Vandenbroucke et al. 2001). The development of real time PCR 
techniques has overcome this limitation and it is now widely used for the quantitation of 
gene expression.  
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1.7.2 Absolute quantification using real time PCR  
The use of real time PCR was first reported in 1992, where the process of amplification 
was monitored by ethidium bromide (EtBr) (Higuchi et al. 1992; Zamorano et al. 1996). 
EtBr is no longer favored for monitoring PCR progress in real time as it fluoresces in the 
presence of both double- and single-stranded DNA. SYBR green I is now the fluorescent 
dye of choice as it binds preferentially to double-stranded DNA, thus replacing EtBr for 
real time PCR detection.  
In real time PCR, the accumulation of products generated during each cycle of the reaction 
process can be reliably correlated with the amount of starting template. Here, the product 
is detected at each cycle by measuring the fluorescence emitted. As the amount of product 
is directly proportional to the intensity of fluorescence emitted, it is possible to measure 
the progress of amplification by real time monitoring of fluorescence. Thus, by measuring 
a defined intensity of fluorescence (Ct, threshold cycle), it is then possible to compare the 
progress of PCR of two separate reactions (Gibson et al. 1996). The Ct values are 
determined at the early stages of amplification or even at the exponential phase of PCR. 
This is the most accurate moment of the reaction for the detection as the reagents for 
amplification are not limited during the exponential phase. Real time PCR offers a wide 




1.8 Aim of this study 
Identification of GFRα1b, a novel spliced receptor isoform of GFRα1(Dey et al. 1998), 
has prompted our investigation into the distribution and function of this isoform. Both 
isoforms share high sequence homologies. The objective of this study was firstly, to 
investigate expression levels of the two isoforms in various human tissues. This will 
enable a better understanding of their potential functions in the tissues. The expression 
levels of the two isoforms and their signaling partner, Ret, were measured in various 
human tissues including adult and fetal brain by real time PCR. Secondly, Western blot 
analyses were carried out to measure the activations of MAPK/Erk1/2, JNK, p38, 
PI3K/AKT in GFRα1a and GFRα1b expressing cells treated with GDNF and NTN to 
determine the signaling pathways used by these two isoforms. Finally, the functional roles 
of the two spliced isoforms in cell morphological differentiation and proliferation were 




















2.1 Molecular techniques 
2.1.1 Agarose gel electrophoresis of DNA 
A 1 % (w/v) agarose gel was prepared by melting 0.3 g of powdered agarose (SeaKem LE, 
BioWhittaker Molecular Application, USA) in 30 ml of 1 x TAE buffer (Appendix I) 
containing 0.25 µg/ml of ethidium bromide (Sigma-Aldrich, USA). The molten agarose 
was poured into a gel casting tray and allowed to set at room temperature. The DNA 
samples premixed with appropriate amount of 6x loading dye (0.25 % bromophenol blue, 
0.25 % xylene cyanol FF and 30 % glycerol) were loaded into the gel and electrophoresed 
in 1x TAE buffer at 80 to 110 volts. The migration of bromophenol blue dye in the 
samples was monitored till it reached the desired distance. The gel was then viewed under 
UV illumination and recorded by ChemiDocTM system (ChemiDocTM MZL, Bio-Rad 
Laboratories, Italy).  
 
2.1.2 DNA recovery from agarose gel  
The desired DNA fragment was gel purified using the Qiagen DNA purification system 
(Qiagen GmbH, Germany) according to the manufacturer’s instruction. After 
electrophoresis, the agarose gel slice containing the desired DNA fragment was excised 
under visualization with UV illumination (300 nm) and weighed. Three gel volume of QG 
buffer was added and incubated with shaking to completely dissolve the gel slice. One gel 
volume of isopropanol was added and mixed. The mixture was then added to the column 
where DNA was bound by hydrophobic interaction with the silica in the column in high 
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salt buffer. The column was then washed to remove impurities and the DNA eluted with 
50 µl of TE buffer (Appendix I). 
 
2.1.3 Ligation of DNA fragment with vector 
DNA fragments isolated from agarose gel were ligated to linearised vector using an insert 
to vector ratio of 5 to 1. Ligation was carried out by mixing appropriate amounts of insert 
DNA and vector in T4 DNA ligase buffer (30 mM Tris-HCl, pH 7.8, 10 mM MgCl2, 10 
mM DTT and 1mM ATP) and 2 - 3 U T4 DNA ligase (Promega, USA) in a 20 µl reaction 
and incubated at 4ºC overnight. Half of the reaction was analyzed on an agarose gel to 
check the extent of the ligation. 
 
2.1.4 Preparation of competent cells using calcium chloride 
One milliliter of overnight E.coli (Appendix II) culture was used to seed a 50 ml of 2 x PY 
media (Appendix I) and grown in an incubator with vigorous shaking (200 rpm) to an 
OD590 of 0.5 at 37°C. Cells were harvested by first chilling on ice for 30 min and then 
centrifuged in a cold rotor at 3,500 X g for 10 min at 4°C. The supernatant was removed 
and the pellet was resuspended gently in 50 ml of cold CaCl2 solution (Appendix I) and 
kept on ice for 20 min before they were pelleted as before. Competent cells were finally 
resuspended in 2.5 ml of cold CaCl2 solution and stored as 100 µl aliquots at -80°C  
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2.1.5 DNA transformation of E.coli cells by heat shock  
The competent E. coli cells prepared by the calcium chloride method (Section 2.1.4) were 
thawed on ice and mixed with DNA. The mixture was allowed to stand on ice for 30 min, 
after which the competent cell was heat shocked at 42oC in a water-bath for 90 sec. 
Immediately after the heat shock, the DNA-competent cell mixture were chilled on ice for 
another 10 min. One milliliters of pre-warmed 2 x PY media (Appendix I) was then added 
to the heat-shocked cell and incubated at 37oC for an hour. At the end of the incubation, 
200 µl of the heat-shock cells were plated onto the 2 x PY agar plate (Appendix I) and 
selection was carried out with the appropriate antibiotics (Appendix I). 
 
2.1.6 Selection of recombinant DNA 
With vectors exploiting blue/white color selections, the bacteria culture was plated on 2 x 
PY agar plate (Appendix I) with 100 µg/ml ampicillin (Sigma-Aldrich, USA) 80 µg/ml X-
gal (Promega, USA) and 1 mM IPTG (Promega, USA). The antibiotic selection 
differentiates between the transformed bacteria and wild type bacteria, while the X-
gal/IPTG selects for transformants with an insert (white colony) and those transformants 
harboring self-ligated vector without insert (blue colony). 
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2.1.7 Isolation of plasmid DNA 
2.1.7.1 Alkaline lysis method (small scale preparation) 
Plasmid preparation from bacterial culture (1-3 ml) was carried out using conventional 
plasmid preparation by alkaline lysis (Birnboim and Doly 1979). Two milliliters of 
overnight bacterial culture was collected by centrifugation at 13,000 X g for half a minute 
and the pellet was subsequently suspended in 100 µl of TE buffer. Cells were then 
thoroughly lysed in 200 µl of lysis buffer (0.5M NaOH and 4 % SDS). One hundred fifty 
microliters of 3 M sodium acetate, pH 4.5, was added and gently mixed to prevent 
shearing of genomic DNA. The precipitate was collected by centrifugation at 12,000 X g 
for 15 min. The supernatant was subsequently extracted with phenol/chloroform (1:1; v/v). 
Plasmid DNA was then precipitated by adding 2.5 volume of 100 % ethanol and 
centrifuged at 13,000 X g for 20 min. The pellet was then washed with equal volume of 
ethanol (70 %) and air-dried at room temperature. The pellet was resuspended in 50 µl of 
TE buffer (Appendix I) containing a RNase cocktail (5 U, Ambion). 
 
2.1.7.2 WizardTM Plus minipreps DNA purification system  
WizardTM Plus minipreps DNA purification system (Promega, USA) provides a simple 
and reliable way for the rapid isolation of plasmid of up to 20 kbp. One to 5 ml overnight 
bacterial culture was centrifuged at 13,000 X g for 2 min. The supernatant was removed 
and the cell pellet was resuspended in 300 µl of cell resuspension solution (50 mM Tri-
HCl, pH 7.5, 10 mM EDTA and 100 µg/ml RNase A). Three hundred microliter of cell 
lysis solution (0.2 M NaOH, 1 %SDS) was then added and mixed gently. After that 300 µl 
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of neutralization solution (1.32 M potassium acetate, pH 4.8) was added and mixed by 
inverting the tube several times. The mixture was then centrifuged at 13,000 X g for 10 
min. The supernatant was transferred into a fresh tube and 1 ml of resuspended resin was 
added. The mixture was transferred to a minicolumn and washed with 2 ml column wash 
solution (80 mM potassium acetate, 8.3 mM Tris-HCl pH 7.5, 40 µM EDTA and 55 % 
ethanol). The minicolumn was then transferred to a centrifuge tube and centrifuge at 
13,000 X g for 3 min to get rid of any residual column wash solution and the DNA was 
eluted in 50 µl TE buffer (10 mM Tris-HCl pH 7.5 and 1 mM EDTA). 
 
2.1.7.3 WizardTM Plus midipreps DNA purification system  
Overnight bacterial culture (10-100 ml) was centrifuged at 13,000 X g for 5 min. The 
supernatant was removed and the cell pellet was completely resuspended in 3 ml of cell 
resuspension solution (50 mM Tri-HCl, pH 7.5, 10 mM EDTA and 100 µg/ml RNase A). 
Three milliliters of cell lysis solution (0.2M NaOH, 1 %SDS) was then added and mixed 
gently. After that 3 ml of neutralization solution (1.32 M potassium acetate, pH 4.8) was 
added and mixed by inverting the tube several times. The mixture was then centrifuged at 
13,000 X g for 15 min. The supernatant was transferred into a fresh tube and 10 ml of 
resuspended resin was added. The mixture was transferred into a column and then washed 
with 15 ml of column wash solution (80 mM potassium acetate, 8.3 mM Tris-HCl pH 7.5, 
40 µM EDTA and 55 % ethanol) twice and centrifuge at 13,000 X g for 3 min to get rid of 
any residual column wash solution. The plasmids DNA was eluted either in 300 µl of TE 
buffer (10 mM Tri-HCl pH 7.5 and 1 mM EDTA) or double distilled water. 
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2.1.7.4 NucleoBond® Plasmids purification system 
Plasmids for transfection were prepared using NucleoBond® Plasmids purification system 
(Clontech laboratories, USA). NucleoBond® AX (Clontech laboratories, USA) is a silica 
based anion exchange resin. The purified nucleic acids products are suitable for use in the 
most demanding molecular biological application, including transfection. The following 
protocol is used to purify plasmids ranging from 3-10 kb. 
Fifty milliliters of overnight bacterial culture were centrifuged at 6,000 X g for 15 min at 
4°C and the supernatant was discarded. The pellet was resuspended in 0.4 ml of Buffer S1 
+ RNase A (50 mM Tris-HCl, 10 mM EDTA, 100 mg/ml RNase A). Buffer S2 (4 ml) 
(200 mM NaOH, 1 % SDS) was then added and mixed by gentle inversion. Buffer S3 
(0.3ml) (2.8 M KAc, pH 5.1) was then added and incubated on ice for 5 min. The mixture 
was centrifuged at 10,000 X g for 20 min. at 4°C. The cleared lysate was loaded into a 
NucleoBond cartridge. The cartridge was washed with 1 ml of Buffer N3 (100 mM Tris, 
15 % ethanol, 1.15 M KCl, adjusted to pH 6.3 with H3PO4) for three times by 
centrifugation. The plasmid DNA was eluted with 0.8 ml of Buffer N5 (100 mM Tris, 15 
% ethanol, 1 M KCl, adjusted to pH 8.5 with H3PO4). 0.6 ml of isopropanol was added to 
the eluate and the mixture was centrifuged at 10,000 X g for 30 min at 4°C. The pellet was 
washed once with 70 % ethanol, air dried and re-dissolved in 50 µl of double distilled 
water. 
 
2.1.8 Restriction enzyme digestion of plasmid DNA 
Plasmid DNA was digested using the recommended buffers according to the 
manufactory’s instructions (Promega USA, or Amersham USA). One to four enzyme units 
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(U) were used per µg of DNA. Restriction digestions were incubated at 37ºC for about 1 
hr (depending on the restriction enzyme) and the reaction was terminated by heating at 70 
ºC for 20 min. The digests were analyzed by agarose gel electrophoresis (Section 2.1.1). 
 
2.1.9 DNA sequencing 
DNA for sequencing was prepared using the Big-Dye sequencing kit (PE Applied 
Biosystems), following the manufacturer’s instructions. Sequencing reaction was carried 
out either with 0.5 µg of circular plasmid DNA or 0.2 µg of PCR products and 10 pmole 
of primer with 8 µl of the reaction pre-mix (Big-Dye) in a total of 20 µl reaction in a 
thermal cycler (PT-100, MJ Research Inc., Watertown, MA, USA) using the following 
parameters, 95oC for 15 sec, 50oC for 30 sec and 68oC for 4 min for 25 cycles. To recover 
the sequencing reaction product, the sample (20 µl) was precipitated with 2 µl of 3 M 
sodium acetate (pH 5.0) (Sigma-Aldrich), and 44 µl of 100 % ethanol (Merck, Germany) 
and the pellet was collected by centrifugation at 13,000 X g for 20 min. The supernatant 
was aspirated, while the pellet was washed with 250 µl of 70 % ethanol, air dried and 
sequenced (NUMI NUS, Singapore). The sequence data was analyzed by using 
DNASTAR (DNASTAR Inc, Madison, WI, USA) and DNAMAN (Version5.2.9, Lynnon 
Biosoft, USA) softwares. 
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2.1.10 Total RNA extraction from mammalian cells using Quantum Prep 
AquaPureTM RNA isolation system 
Total RNA was extracted from cultured cells using AquaPureTM RNA isolation kits (Bio-
Rad, USA). Cells were grown in 75 cm2 tissue culture flask untill confluent. Growth 
medium was removed and 1.5 ml of RNA lysis solution (Citric acid 2.5-5 %, EDTA 2.5-5 
%, SDS 2.5-5 %) was added to the cells and the lysate was transferred to a tube. Five 
hundred microliter of protein-DNA precipitation solution (NaCl 20-35 %, citric acid 2.5-5 
%) was then added and mixed gently. The mixture was placed on ice for 5 min and then 
centrifuged for 3 min at 13,000 X g. The supernatant containing RNA was transferred to a 
fresh tube and 1.5 ml of 100 % isopropanol was added. The mixture was then centrifuged 
at 13,000 X g for 10 min. The pellet was washed with 70 % ethanol; air dried and 
resuspended with 50 µl of RNA hydration solution. The concentrations and purity of the 
RNA were determined by spectral wavelength scan from 220 to 320 nm and calculated 
based on 1OD260 is equal to 40 µg/ml of RNA. The integrities of the total RNA were 
validated by denaturing agarose gel electrophoresis (Section 2.1.11). 
 
2.1.11 Agarose gel electrophoresis of RNA 
Denaturing agarose-formaldehyde gel was used for RNA electrophoretic analysis. A 1% 
(w/v) agarose (SeaKem LE, BioWhittaker Molecular Application, USA) formaldehyde gel 
was prepared in 1 x MOPS buffer (Appendix I) containing 1.5 % formaldehyde (v/v, 
Sigma Chemical Co. Germany). RNA loading sample was prepared by mixing the total 
RNA (2-10 µl, up to 20 µg) with 25 µl loading buffer (Appendix I) containing 0.03 mg/ml 
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of ethidium bromide (Sigma Chemical Company, USA) and electrophoresis in 1 x MOPS 
buffer. The gel was viewed and recorded by ChemiDocTM system (ChemiDocTM MZL, 
Bio-Rad Laboratories, Italy). 
 
2.1.12 Reverse transcription (RT) of RNA 
Ten microgram of total RNA was heat denatured with 0.5 µg of random hexamer 
(Promega, USA) at 65oC for 5 min and snap chilled on ice for 2 min. Reverse transcription 
was carried out in 5 mM DTT (Invitrogen Corporation, USA), 40 unit of RNase inhibitor 
(Promega, USA), 10 mM of dNTP (Promega, USA) and 400 U of SuperscriptTM II reverse 
transcriptase (Invitrogen Corporation, USA) in a final volume of 40 µl. The reaction was 
incubated at 42oC for 60 min and terminated by heating at 70oC for 5 min. 
 
2.1.13 Polymerase chain reaction (PCR) amplification  
A typical PCR amplification was performed in a 100 µl reaction volume containing 10-20 
ng of DNA template, 0.1-0.5 µM of each primer, 2mM MgCl2, 0.2 mM dNTP, 1 x Taq 
polymerase buffer and 2.5 units of Taq polymerase (Promega, USA). PCR reaction was 
carried out after an initial denaturation for 5 min at 95oC followed by 30 cycles of 30sec 
denaturation at 95oC, 1 min at 55°C, and 2 min extension at 72oC with one final cycle for 
10 min at 72°C in a thermal cycler (PTC-100 TM Programmable thermal Controller, MJ 
Research Inc., USA). The amplified product was analyzed by agarose gel electrophoresis 
(Section 2.1.1). 
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In the case of reverse transcription PCR, 5-10 µl of cDNA was used directly as the 
template for a total reaction volume of 100 µl. 
 
2.2 Protein chemistry techniques 
2.2.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Discontinuous one-dimensional gel electrophoresis was carried out using Bio-Rad Mini-
Protean apparatus (Bio-Rad Laboratories, USA) with an acrylamide resolving gel and 5% 
(w/v) stacking gel (Appendix I). The percentage of acrylamide – bisacrylamide (Bio-Rad 
Laboratories, USA) in resolving gel was chosen depending on the molecular weight of the 
protein of interest. For the present study, a 10-12 % of resolving gel (Appendix I) was 
used. 
Samples were suspended in SDS sample buffer (Appendix I), heated at 95°C for 5 min, 
briefly centrifuged, loaded and electrophoresed at 100 volts until the dye front migrated in 
to the resolving gel, then the voltage was increased to 180 volts until the dye reached the 
bottom of the resolving gel.  
 
2.2.2 Western blotting and detection 
Following SDS-PAGE, the gel was removed and equilibrated in transfer buffer (Appendix 
I) for 10 min at room temperature with constant shaking. A piece of nitrocellulose 
membrane (Hybond-C Extra, Amersham Pharmacia Biotech UK) was placed on top of the 
gel, covered by a filter paper and placed between a semidry transfer apparatus (Bio-Rad 
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Laboratories, USA). The transfer was carried out at 100 volts for 60 min. The membrane 
was then incubated in TBST solution (Appendix I) with 5 % fat-free skimmed milk (w/v, 
Diploma Instant, Melbourne Australia) for 1 hr at room temperature to reduce non-specific 
binding of antibody in subsequent steps. The membrane was then washed 3 times in TBST 
(Appendix I) and incubated with the primary antibody (1 : 1000 dilution in TBST, 1% 
(w/v) skimmed milk) for 1 hr at room temperature or overnight at 4ºC on a rocking 
platform. After the incubation, the membrane was washed for 3 x 5 min in 1 % (w/v) 
skimmed milk in TBST. The secondary antibody conjugated with horseradish peroxidase 
(HRP) (DAKO, Denmark) at 1:1000 dilution in 1 % skimmed milk (w/v) /TBST was then 
added and incubated for 1 hr at room temperature. The membrane was then washed for 3 x 
5 min in TBST and detected by Super Signal® West Dura Extended Duration 
chemiluminescent substrate (Pierce, USA) according to manufacturer’s instruction. The 
chemiluminescent image was captured on Biomax film (MR 1, Kodak). 
 
2.2.3 Protein quantification by BCA assay 
BCATM Protein Assay Reagent Kit (Pierce, USA) was used to determine protein 
concentration. The protein assay is based on bicinchoninic acid (BCA) for the colorimetric 
detection and quantitation of total protein. This method combines the reduction of Cu2+ to 
Cu+ by protein in alkaline medium with the highly sensitive and selective colorimetric 
detection of the cuprous (Cu+) using bicinchoninic acid. The macromolecular structure of 
protein, and number of peptide bonds and the presence of four amino acids (cysteine, 
cystine, tryptophan and tyrosine) have been reported to be responsible for color formation 
in protein sample when assayed with BCA (Wiechelman et al. 1988). The purple reaction 
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product, formed by the interaction of two molecules of BCA with one cuprous ion (Cu+), 
is water-soluble and exhibits a strong absorbance at 562 nm. This allows the 
spectrophotometric quantification of protein in aqueous solutions. 
The working reagent was prepared by combining 50 parts of reagent A (sodium carbonate, 
sodium bicarbonate, bicinchoninic acid and sodium tartrate in 0.2 M sodium hydroxide) 
with one part of reagent B (4 % cupric sulfate solution). Serial dilutions (20-2000 µg/ml) 
of protein standard (BSA) and samples were assayed in parallel. Twenty five microliters 
of each standard or unknown sample was pipetted into the appropriate microtiter plate 
wells and then 200 µl of working reagent was added to each well and mixed for 30 sec. 
The plate was incubated at 37°C for 30 min and absorbance was read at 562 nm with a 
microtiter plate reader (Model 680, Bio-Rad, USA). Standard curve was prepared by 
plotting the absorbance at 562 nm vs. protein concentration and protein concentration of 
each unknown samples were interpolated. 
 
2.3 Mammalian cell culture 
2.3.1 Mammalian cell line 
The murine neuroblastoma cell line, Neuro 2a (American Tissue Culture Collection, CCL-
131) was used for transfection studies. Cells were cultured and maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (Hyclone, 
USA) in a 37oC humidified incubator with 5% CO2. 
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2.3.2 Cell transfection by FuGENE 6® Transfection Reagent  
FuGENE 6 Transfection Reagent (Roche, Germany) is a multi-component lipid-based 
transfection reagent that complexes with and transports DNA into the cell during 
transfection. In general, 0.2 x 106 cells in 2 ml of 10 % FBS/DMEM growth media were 
seeded in 6-well tissue culture plates for 16 hours. FuGene 6 reagent and purified 
plasmids DNA (Section 2.1.7.4) complex were prepared in serum free media with a ratio 
of 3 : 1 (µl : µg) for each well and incubated for 30 min at room temperature. The 
complex mixture was then added drop-wise to the seeded cells in 6-well plates. A negative 
control of transfection was carried out simultaneously in the plates at the same conditions 
and containing all the components except plasmid DNA. The cells were cultured for 
another two days in the same plate and then trypsinized with 0.2 ml 1 x trypsin (0.5 g of 
Trypsin and 0.2 g EDTA 4Na /liter) (Gibco, Invitrogen Corporation). The detached cells 
were then transferred to a 75 cm2 tissue culture flask containing 10 ml of the growth 
media with 0.8 mg/ml G418-sulfate (Promega, USA). The selection was carried out by 
continuously culturing cells in the growth medium containing G418 and the selection 
media was renewed every three days. The stably transfected cell population was 
considered established when the negative control cells were completely eliminated by the 
selection medium. 
 
2.3.3 Haemocytometer for cell count 
Adherent cells grown in the flask were trypsinized (Section 2.3.2) and cell suspension 
were mixed by tituration. Equal volume of the cell suspension and trypan blue (0.4%, w/v 
in 0.85% NaCl solution) (Sigma, USA) were mixed and incubated for 5 min at room 
 32
temperature. The mixture was then transferred to the haemocytometer chamber (Sigma, 
USA) and viable cells (not stained) were counted, while dead cells were stained blue in 
color. The average cell number per large square was calculated and the result is then 
multiply by 10,000 for the final cell number in 1 ml of the cell suspension. 
 
2.3.4 Cell Proliferation measured by Cell Proliferation BiotrakTM ELISA 
System 
Cell Proliferation BiotrakTM ELISA system (Amersham Biosciences, UK) is designed as a 
precise, fast and simple colorimetric alternative to quantitate cell proliferation based on 
the measurement of 5-bromo-2’-deoxyuridine (BrdU) incorporation during DNA synthesis 
in proliferating cells. This technique is based on the incorporation of the pyrimidine 
analogue BrdU instead of thymidine into the DNA of proliferating cells  
Five thousand cells in 200 µl of 2 % FBS /DMEM containing 0.8 mg/ml of G418 were 
seeded in a 96-well microtiter plate and incubated at 37°C in 5 % CO2, 95 % air 
humidified atmosphere. After 16 hours incubation, the medium was replaced and cells 
were stimulated by various concentrations of GDNF and NTN in the same culture medium. 
The incubation was continued for the desired period of time. Twenty microliters of 
labeling medium containing 100 mM BrdU was added directly to each well before the end 
of each time point and incubated for a further two and a half hour. The microtiter plate 
was centrifuged at 1,500 X g for 5 min and the labeling medium was removed. Two 
hundred microliters of fixative solution per well was added and incubated for 30 min 
followed by the addition of 200 µl/well blocking buffer in the wells for a further 30 min at 
room temperature. After removing the blocking buffer, 100 µl/well of the peroxidase-
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labeled anti-BrdU working solution was added to the wells. The plate was incubated for 
90 min at room temperature and then washed three times with 200 µl/well washing 
solution. The substrate, of 3,3’5,5’-tetramethylbenzidine (TMB,100 µl/well) was then 
added to the wells for color development at room temperature and reaction was terminated 
by the addition of 25 µl of 1M sulphuric acid. The optical density was measured in a 
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GFRα1 was first discovered as an essential receptor mediating the effect of GDNF. The 
neurotrophic activities of GDNF are mediated by binding to GFRα1 specifically and 
further activation of the c-Ret protein-tyrosine kinase (Jing et al. 1996; Treanor et al. 
1996). GFRα1a and GFRα1b are two highly homologous spliced isoforms of GFRα1 
receptor with GFRα1a containing an extra 15 nucleotide (exon 5) compared to GFRα1b 
(Dey et al. 1998). Previous studies using PCR and in situ hybridization techniques have 
shown that GFRα1 is widely distributed in neuronal and non-neuronal tissues both in 
human and mouse. These studies however, could not differentiate between the two 
isoforms of GFRα1 as the experiments detected only the common regions of GFRα1. 
Currently, the expression levels of GFRα1 spliced isoforms, GFRα1a and GFRα1b are 
unknown in any animal and human tissues. This is the first study to measure and compare 
the transcriptional expression levels of the two GFRα1 isoforms in human tissues.  
Real time quantitative PCR is a highly sensitive method for rapid, accurate and 
reproducible quantification of gene expression. The accumulation of PCR products can be 
visualized at each cycle by measuring the fluorescence emitted with a fluorometer coupled 
to the thermal cycler. The reaction is then characterized in the exponential phase of PCR 
amplification by the threshold cycle number (Ct) rather than the amount of product 
accumulated at the end of the PCR (Gibson et al. 1996). In principle, there are two 
fluorescent detection systems available for monitoring the progression of DNA 
amplification in real time PCR. One system uses the DNA binding dye, SYBR green I. 
SYBR green I binds to the minor grove of double-stranded DNA in a sequence 
independent manner. Once SYBR green I binds to the DNA, its fluorescence increases 
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over 100-fold, allowing sensitive and accurate detection of double-stranded DNA in the 
reaction. Same time, however any nonspecific amplification during the PCR will also be 
detected in addition to the desired product. Another system uses fluorogenic dye labeled 
sequence-specific hybridization probes, including TaqMan, Molecular Beacons, 
LightCycler and Amplifluor (Gibson et al. 1996). These are based on fluorescence 
resonance energy transfer (Selvin 1995). As it allows the specific detection of the 
amplification of the target DNA based on specific hybridization of a fluorogenic probe to 
the product, also called sequence-dependent detection method. This approach has been 
extended to the detection of multiple DNA targets in the same reaction by using specific 
probes that have non-overlapping fluorescent spectrums. Quantitation of an unknown 
sample can be achieved by co-amplifying a series of standards and the unknown, and the 
starting amounts of the unknown was interpolated from the standard curve of Ct values. 
To measure the individual expression level of the two spliced isoforms of GFRα1, one 
approach is to use a specific fluoroprobe that detects the unique sequences in exon 5, 
which is presented in GFRα1a but not in GFRα1b isoform and a pair of common primers 
for amplification (Fig.3.1). However, we found that the accuracy of quantifying GFRα1a 
using this method was severely limited by the presence of increasing amounts of the 
related template (GFRα1b). Hence, an exon overlapping sense primer and a common 
antisense primer for amplification were designed to achieve high specificity and accuracy 
for detecting either one of the two isoforms in the human tissues by real time PCR using 




3.2 Materials and Methods 
3.2.1 Real time PCR 
Real time PCR was performed using the iCycler iQ (Bio-Rad, USA). The threshold cycles 
(Ct) were calculated using the optical interface v3.0a (Bio-Rad, USA). Real time PCR was 
carried out after an initial denaturation for 5 min at 95oC followed by 40 cycles of 60sec 
denaturation at 95oC, 30sec annealing at 60oC and 60sec extension at 72oC. This cycling 
parameter was found to be optimal for the amplifications of targets between 100 to 600 bp 
in our study. The annealing temperature was set at 5 ºC lower than the melting 
temperature (Tm) of the primers, which was calculated using DNAMAN (Version5.2.9, 
Lynnon Biosoft, USA). Primers were designed to have similar Tm values. The extension 
time was chosen based on the speed of polymerization of 1min/kb. Fluorescent detection 
was carried out at the annealing phase. 
 
3.2.2 Standards for real time PCR 
Plasmids DNA (Section 2.1.7) were used as standard templates for the study. Specific 
sequences to the target genes were generated by PCR (Section 2.1.13), purified from 
agarose gel (Section 2.1.2) and subcloned into pGEM-T vector (Promega, USA). All 
standard DNA templates were verified by DNA sequencing analysis (Section 2.1.9). The 
primers and sequences used as standards of real time PCR were listed in Appendix III. 
The concentrations and purity of plasmids DNA were determined by spectral wavelength 
scan from 220 to 320nm and calculated based on 1OD260 being equal to 50µg/ml of DNA. 
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3.2.3 Reverse transcription (RT) of total RNA of human tissues and cell 
samples 
Ten micrograms of human total RNA (Clontech USA) or total RNA extracted from tissue 
culture cells were reverse transcribed using the method described in section 2.1.10. The 
reaction was terminated by heating at 70˚C for 5 min and subsequently treated with 2 U of 
RNase H (Invitrogen Corporation USA) for 30 min at 37˚C. Varying amounts (0.08 to 2 
µl, <5% of the total PCR reaction volume) of the reverse transcribed products were 
directly quantified by real time PCR using SYBR Green I. 
The integrities of all human total RNA were initially validated by denaturing agarose gel 
electrophoresis as described in the section 2.1.11. 
 
3.2.4 Sequence dependent real time PCR using specific TaqMan probe for 
detection 
A specific minor grove binding (MGB) TaqMan probe (5’-
6FAMtgctggaaaacatcMGBNFQ-3’, Applied Biosystems, USA) hybridizing to exon 5 was 
designed to specifically detect GFRα1a isoform. A set of common primers, GFRα1-318F 
(5'-ggagcatgtaccagagcct-3') and GFRα1a-567R (5'-acttcattggacatgctggt-3') was used for 
the amplifications of both GFRα1a and GFRα1b isoforms. The positions of the primers 
and probe were shown in Fig. 3.1. The complete open reading frames (ORF) of GFRα1a 
(GenBank accession number AF014117) and GFRα1b (GenBank accession number 
AF015172) were generated by PCR and subcloned into the mammalian expression vector 
pIRESneo (Clontech, USA). The plasmids, pGFRα1a (encoding the complete ORF of 
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GFRα1a) and pGFRα1b (encoding the complete ORF of GFRα1b) were verified by DNA 
sequencing (Section 2.1.9). Both pGFRα1a and pGFRα1b were linearized with the 
restriction enzyme Xba I (Promega, USA) as described in section 2.1.8 and used as 
templates for the real time PCR detected by the specific TaqMan probe. The reaction 
volume of 50 µl contained 200 nM of the TaqMan probe, 80nM of each primer and 25 µl 
of TaqMan Universal PCR Master Mix (Applied Biosystems, USA). 
 
3.2.5 Sequence independent real time PCR using SYBR Green I for 
detection 
The sequence independent real time PCR was carried out under the same cycling 
conditions as described in section 3.2.1 except that fluorescent detection uses SYBR 
Green I at the extension phase. The reaction was performed in a total volume of 50 µl 
containing 1 x XtensaMix-SGTM (Bioworks, Singapore), 2.5 mM MgCl2, 0.5 U 
DyNAzyme II (Finnzymes, Finland), 80nM or 160nM of each primer. Standard templates 
of human GFRα1a (Genbank accession number AF038421) and GFRα1b (Genbank 
accession number BC014962) were generated by RT-PCR (Section 2.1.12 and 2.1.13) 
from human brain total RNA using the specific primers hGFRα1a-411F (5'-
catatcagatgtttttcagcaa-3')/ hGFRα1a-560R (5’-cagacatcgttggacacg-3’) and primers 
hGFRα1b-401F (5'-tggtcccattcatatcagtgga-3')/ hGFRα1a-560R (5’-cagacatcgttggacacg-3’), 
respectively. The positions of the GFRα1 primers were shown in Fig.3.1. Similarly, the 
templates for human c-Ret (Genbank accession number XM_049008) and GAPDH 
(Genbank accession number M33197 for human and M32599 for mouse) were generated 
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by RT-PCR using the following pairs of primers, RET-NF (5’-ttcatcgggacttggcagc-3’) and 
RET-NR (5’-accatacatcactttgcgtg-3’) for human c-Ret (Fig. 3.2) and forward primer 
GAPDH-F (5’-gatggcatggactgtggtca-3’) and degenerate reverse primer GAPDH-R (5’-
satgggtgtgaaccaygagaa-3’) for both human and mouse GAPDH. For studies using stably 
transfected Neuro2a cells (mouse neuroblastoma cells), the same strategy was used to 
generate mouse specific standard templates based on the sequences of GFRα1a (Genbank 
accession number AF014117), GFRα1b (Genbank accession number AF015172) and c-
Ret (Genbank accession number AF209436). Three sets of specific exon overlapping 
primers were designed as mGFRα1a-421F (5'-catatcagatgttttccagca-3') and mGFRα1a-
567R (5'-acttcattggacatgctggt-3') for amplifying GFRα1a, mGFRα1b-409F (5'-
cagtcccgttcatatcagtgga-3') and mGFRα1a-567R (5'-acttcattggacatgctggt-3') for amplifying 
GFRα1b, and MouRetFor (5’-catcgggacttagctgcc-3’) and MouRetRev (5’-
aagggactcaattgccatccac-3’) for amplifying the common region of mouse c-Ret. 
All the amplified products were subcloned into pGEM-T (Promega, USA) and validated 
by DNA sequencing analysis. All standard templates were linearized with restriction 
enzyme Xmn I (Promega, USA) and quantified by spectrophotometer at 260 nm prior to 
detection. Real time PCR detections of human tissue and cell culture samples were 
performed in parallel with standard templates and negative controls (non-RT samples) in 
duplicates. For human tissue samples, three separate RT reactions were carried out and a 
total of eight independent measurements were performed by real time PCR for each tissue 
sample. For cell line samples, measurements were carried out in duplicates from two 
separate RT preparations. The expression levels of GFRα1 isoforms and c-Ret in each 





1 2 3 4 5 6 7 8 9 10 11 
hGFRα1b-401F hGFRα1a-560R 


















Fig.3.1 Exon organization of human GFRα1a (A) and GFRα1b (B) spliced isoforms and locations of 
the primers and the specific MGB TaqMan probe (shaded square). Exon 5 is absent in GFRα1b. The 
specific exon overlapping primer for GFRα1a (hGFRα1a-411F) was designed across the junction of 
exon 4 and 5, and the exon overlapping primer for GFRα1b (hGFRα1b-401F) was designed across the 







Fig.3.2 Exon organization of c-Ret isoforms, Ret 51, Ret 43 and Ret 9, the common primers Ret-NF 
































































































Table 3.1 Sequences and concentrations of the primers used in real time PCR reaction (50ul)  
 
3.2.6 Statistical analysis 
Differences in the expression levels of GFRα1a and GFRα1b within each human tissue 
sample were calculated using the paired two-tailed t-test. 
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3.3 Results  
To ensure accurate and reliable quantitation of the expression levels of the GFRα1 spliced 
isoforms, both sequence dependent (using specific probe) and sequence independent real 
time (SYBR green I) PCR analyses were initially explored. Results in this study showed 
that the sequence dependent real time PCR was unreliable for the detection of highly 
homologous sequences, such as GFRα1a and GFRα1b, when common primers were used 
for amplification. In contrast, sequence independent real time PCR using SYBR green I 
with specific exon overlapping primer for amplification was highly specific. 
 
3.3.1 Sequence dependent real time PCR quantitation using specific probe  
One approach to detect the two spliced variants, GFRα1a and GFRα1b, is to use a specific 
fluorogenic MGB TaqMan probe (Section 3.2.4) with an unique oligo sequence 
hybridizing to exon 5 of GFRα1a. This allows the specific detection of GFRα1a but not 
GFRα1b. A set of common amplification primers for the two GFRα1 isoforms, GFRα1-
318F (5'-ggagcatgtaccagagcct-3') and GFRα1a-567R (5'-acttcattggacatgctggt-3') were 
designed. This pair of primers annealed to both GFRα1a and GFRα1b with equal 
efficiency and was used for amplification (Fig.3.1). 
 
3.3.1.1 Amplification efficiency using the common primers  
The efficiency of amplifying the two spliced isoforms, GFRα1a and GFRα1b using 
common primers, GFRα1-318F and GFRα1a-567R were tested by sequence independent 
real time PCR using SYBR Green I (Section 3.2.5). Plasmids pGFRα1a and pGFRα1b 
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(Section 3.2.4) containing the complete ORF of the isoforms GFRα1a or GFRα1b, 
respectively, were used as standard templates for the reaction. Amplification of both 
templates with serial dilutions showed very similar amplification efficiency by the primers 
(Fig. 3.3). Agarose gel electrophoresis of the PCR amplified products stained by ethidium 
bromide showed the expected product sizes. Water control was carried out simultaneously 















Fig.3.3 Amplification of five log dilutions (1-5) of standard control plasmids pGFRα1a and H2O 
control (Amplification of standard plasmids pGFRα1b was carried out at the same condition and 
resulted a similar amplification pattern-not shown) 
A common pair of primers, GFRα1-318F and GFRα1a-567R was used for amplification and the PCR 
products were detected by SYBR Green I. Amplification efficiencies were Ea=3.94 and Eb=4.02 for 
GFRα1a and GFRα1b respectively. The efficiency of real time PCR is indicated by the slope of the 
curve plotted by Threshold Cycle (Ct) versus log number of molecules by linear regression with 



















Fig. 3.4 Agarose gel electrophoresis of amplified products by real time PCR using various dilutions of 
pGFRα1a as standards (Lanes A1 to A5), pGFRα1b as standards (Lanes B1 to B5) and water control 
(H2O) with molecular marker (M). 
 
 
3.3.1.2 Determining the optimum concentration of the specific MGB TaqMan 
probe used for the detection 
An initial study was conducted to optimize the concentration of the MGB TaqMan 
fluorogenic probe used. This was necessary as the accuracy and sensitivity of the assay 
may be affected by the suboptimal concentration of probe used. A concentration of 200 
nM of the specific MGB TaqMan probe was found to be optimal, with high signal to noise 
ratio (Fig 3.5) and yet have similar efficiency of amplification when compared to SYBR 
green I (data not shown). 
 
3.3.1.3 Detection of the two isoforms with the specific MGB probe using 
common primers for amplification is not reliable  
To verify the specificity of amplifications and detections by using the common primers for 
GFRα1a, amplification was carried out using varying ratios of the two GFRα1 isoforms 
(plasmids) in the same reaction tube. The result showed that increasing amounts of related 
isoforms, GFRα1b, significantly affected the amplification of the target isoforms, GFRα1a. 











was dramatically reduced (Fig.3.6). In this study, the presence of an equal molar of 
pGFRα1b to pGFRα1a affected the maximal fluorescence but not the Ct value. However, 
the detection of pGFRα1a was severely affected by the presence of 10 folds or greater 
molar excess of pGFRα1b. The decrease in fluorescence was due to the failure of 
amplifying pGFRα1a. Hence, the use of specific fluorogenic probe for detection and 
common primers for amplification was not reliable when one of the highly homologous 
























Fig.3.5 Optimization of the specific probe concentration for the sequence dependent real time PCR 
Plasmids pGFRα1a (56 attomole) were as templates using the common primers for the amplification, 

























Fig.3.6 Real time PCR detection using GFRα1a specific MBG probe. 
Amplification was carried out with the common primers (mGFRα1-318F and mGFRα1a-567R). (A) 
Amplification of pGFRα1a (56 attomole) alone; (B) equal molar of pGFRα1a and pGFRα1b; (C) 10 
fold molar excess of pGFRα1b to pGFRα1a; (D) 100 fold molar excess of pGFRα1b to pGFRα1a. No 
fluorescent signal was detected with the sample containing no template (E). The experiment was 
repeated at least three times with similar results. 
 
3.3.2 Sequence independent real time PCR quantitation using SYBR 
Green I 
3.3.2.1 Amplification specificity and efficiency of sequence independent real 
time PCR 
The sequence dependent real time PCR using specific MGB probe and common 
amplification primers is not a reliable method for the detection of GFRα1a and GFRα1b 
(Fig.3.1). We therefore explored the possibility of using exon overlapping primers for 
amplifying each of the isoforms with SYBR Green I detection. The specific primers were 
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designed to overlap two adjacent exons at splicing junction region to achieve specificity in 
amplification. The forward primers hGFRα1a-411F, spans exon 4 and exon 5 junction 
region of GFRα1a, and hGFRα1b-401F , spans exon 4 and exon 6 junction of GFRα1b 
(Fig.3.1 and section 3.2.5). A common reverse primer hGFRα1a-560R (Fig.3.1 and 
section 3.2.5) was designed for both isoforms. The exon overlapping primers allowed the 
specific amplifications of both isoforms.  
The specificity of amplifications of human GFRα1a and GFRα1b isoforms were examined 
using these exon overlapping primers. The use of specific exon overlapping primers for 
either GFRα1a or GFRα1b resulted in highly specific amplifications of the correct targets 
(Fig.3.7A and C). However, PCR with the exon overlap amplification primer to GFRα1a 
(hGFRα1a-411F) and the common reverse primer hGFRα1a-560R poorly amplified 
GFRα1b. Similarly, PCR with the exon overlap amplification primer to GFRα1b 
(hGFRα1b-401F) and the common reverse primer hGFRα1a-560R amplified GFRα1a 
poorly. The degree of discrimination between the two isoforms was greater than 100,000 
fold (Fig.3.7 B and D). 
The standard curves generated using standard templates of GAPDH and c-Ret were shown 
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Fig.3.7 Amplification and detection of GFRα1a and GFRα1b using specific exon overlapping primers 
(A) Amplifications of five log10 dilutions of GFRα1a standards (1-5, highest amount used was 56 
attomole) with the specific primers, hGFRα1a-411F and hGFRα1a-560R, water control without 
template. (B) Amplification of GFRα1a and GFRα1b using GFRα1a specific exon overlapping 
primers. Equal moles (56 attomole) of GFRα1a or GFRα1b were amplified separately. GFRα1b was 
poorly amplified (< 105 fold less than GFRα1a) with ∆Ct = 20.24 ± 0.12. (C) Amplifications of five log10 
dilutions of GFRα1b standards (highest amount used was 56 attomole) and water control without 
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moles of GFRα1a or GFRα1b were amplified separately. GFRα1a was poorly amplified (< 105 fold less 
than GFRα1b) with ∆Ct = 19.14 ± 0.55. (E) Standard curve of amplification. Efficiency of GFRα1a 
standard is presented by the slope of Ct (Threshold Cycles) versus log10 number of molecules with Ea= 
3.97 ± 0.13 and r2 = 0.98. (F) Standard curve of amplification. Efficiency of GFRα1b standard is 
presented by the slope of Ct versus log10 number of molecules, Eb=3.69 ± 0.04 with r2 = 0.99. The 







Fig.3.8 Amplification of GAPDH and c-Ret standards by real time PCR 
(A) Amplifications of five log10 dilutions of GAPDH standards (1 to 5, highest amount of templates 
used was 126 attomole) with the specific primers, GAPDH-F and GAPDH-R, water control without 
template. The expected amplified product size is 148 bp. (B) Amplifications of five log10 dilutions of c-
Ret standards (1-5, highest amount used was 126 attomole) with the specific primers, RET-NF and 
RET-NR, water control without template. The expected PCR product size is 175 bp. (C) Standard 
curve of GAPDH. (D) Standard curve of c-Ret. Standard curve was plotted as Ct versus the log 
number of molecules of templates 
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3.3.2.2 Expression levels of GFRα1a, GFRα1b and c-Ret in various human 
tissues  
The strategy of sequence independent real time PCR using SYBR Green I for detection 
was used to determine the expression levels of GFRα1a, GFRα1b and c-Ret in various 
human tissues. Mapping the distributions and determining the expression levels of the two 
isoforms and c-Ret will enable us to gain better understandings of the mechanisms and 
physiologic roles of GDNF family in these tissues. 
The steady state expression levels of both isoforms and c-Ret in various human tissues 
were determined by the sequence independent real time PCR using specific exon 
overlapping primers (Section 3.2.5). All human tissue cDNA samples (Section 3.2.3) were 
diluted and amplified in parallel with the standard templates. The expression of GFRα1b 
was significantly higher than GFRα1a in the peripheral tissues (Fig.3.10). In the adult 
liver, the expression of GFRα1b transcript was significantly greater than GFRα1a. The 
ratios of GFRα1b to GFRα1a in adult liver and fetal liver were approximately 52 fold 
(Fig.3.10A) and 18 fold (Fig.3.10B), respectively. In heart, kidney, testis and small 
intestine, the ratios of GFRα1b to GFRα1a transcripts were about 6, 20, 8 and 13, 
respectively. However, in the adult human brain, the differences in the expression levels 
were less, with has twice the amount of GFRα1b as GFRα1a. Both isoforms were 
expressed similarly in the fetal brain (Fig.3.10B). The differences in the expression levels 
of c-RET and GFRα1a were less. GFRα1a and c-RET were expressed at equivalent levels 
in the fetal brain. In the adult human brain, c-RET levels were about 4 fold higher than 
GFRα1a (Fig.3.10B). In the other tissues, c-RET expression was found to vary between 2-
5 fold higher than GFRα1a.  
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150bp
GFRα1a 
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GAPDH 
Gel electrophoresis of the amplified PCR products of GFRα1a, GFRα1b, c-Ret and house 
keeping gene GAPDH showed the products of the expected sizes (Fig.3.9). Primer-dimers 
were detected in samples with no template present. All measurements were interpolated 
from the standards and the detection limits of the assays were about 700 molecules (last 













































Fig.3.9 Post PCR analysis. Ethidium Bromide stained agarose gel electrophoresis of real time PCR 
products of eight human tissue samples and their respective standards as templates. Amplifications of 
GFRα1a, GFRα1b, c-Ret and GAPDH using their specific primers in eight human tissues (lanes S1 to 
S8) were carried out simultaneously with their standards (lanes 1 to 5) and water control (H2O). Ten 
micro litter of each fifty micro litter PCR reaction mix was taken for gel analysis.  Single band of 
expected sizes of GFRα1a, GFRα1b, c-Ret or GAPDH respectively were observed with respective 
templates.  100bp marker was used as molecular ruler (lane M).  
Human tissue samples: S1-Liver; S2-Heart; S3-Kidney; S4-Testis; S5-Small Intestine; S6-Brain; S7-
Fetal Brain; S8-Fetal Liver. 
 
 
Fig.3.10 GFRα1 isoforms and c-Ret expression levels in various human tissues.  
The number of molecules (y-axis, mean ± SEM) indicated the relative expression levels of GFRα1a 
(filled bars), GFRα1b (unfilled bars) and c-Ret (hatched bars) normalized to 106 molecules of 
GAPDH expressed in the same tissue. The expression levels of GFRα1a, GFRα1b and c-Ret in the 




























































































































In Vitro Functional Studies 













Neuro2a, a mouse neuroblastoma cell line has been extensively used as a model to study 
neuronal growth and differentiation and to investigate the role of neurotrophic factor 
involved (Gomez et al. 1998; Encinas et al. 2001; Pezeshki et al. 2001). In this study, 
stably transfected neuro2a cell lines were established to investigate the mechanisms 
involved in signaling pathway, functional roles involved in cell morphological 
differentiation and proliferation for the two GFRα1 spliced isoforms, GFRα1a and 
GFRα1b. 
Results from this study revealed significant differences in the functional roles of GFRα1a 
and GFRα1b in morphological differentiation of Neuro2a transfected cells. 
 
4.2 Materials and Methods 
4.2.1 Stable transfected cell lines of GFRα1 two spliced isoforms  
Plasmids, pGFRα1a and pGFRα1b (Section 3.2.4) containing the complete open reading 
frame of the two spliced isoforms GFRα1a and GFRα1b respectively, with cloning sites of 
EcoRI and BamHI of pIRESneo vector (Clontech, USA) were purified using 
NucleoBond® (Section 2.1.7.4). These purified plasmids were confirmed by DNA 
sequencing (Section 2.1.9) and then transfected into Neuro2a cells (Section 2.3.1) with 
Fugene 6 transfection reagent (Section 2.3.2). A control cell line containing only the 
parental vector pIRESneo was transfected in parallel with the two isoforms. Three 
independent transfected cell populations were established. The cell lines were labeled with 
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the prefix ‘N’ to designate the type of receptor transfected (e.g. N-GFRα1a for GFRα1a 
transfected Neuro2a cells). 
Stably transfected cells grown in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum (Hyclone, USA) were established by selection 
using 0.8mg/ml G418 (Section 2.3.2). 
Transfection and expression levels of the transfected foreign DNA were verified by real 
time PCR. Cell lines with similar expression level of GFRa1a and GFRa1b were used 
throughout the study. 
 
4.2.2 Quantitation of expression levels of the two spliced isoforms and c-
Ret in the transfected cells by real time PCR 
The three stably transfected cell lines, N-GFRα1a, N-GFRα1b and N-pIRES were 
established by selection with 0.8mg/ml G 418 (Section 4.2.1). Different pools of G 418 
resistant clones from the cell lines were tested for expression levels of the two isoforms, 
GFRα1a and GFRα1b, and endogenous c-Ret. 
Total RNA of the transfected cells was extracted from cultured cells (Section 2.1.10) and 
the integrities of the all total RNA samples were validated by denaturing agarose gel 
electrophoresis (Section 2.1.11). To measure the transcriptional expression levels of the 
two spliced isoforms and c-Ret, the total RNA was converted to cDNA by reverse 
transcription (Section 2.1.12). Varying amounts (0.08 to 2 µl, <5% of the total PCR 
reaction volume) of the cDNA were then directly quantified by sequence independent real 
time PCR using the specific exon overlapping primers for amplification (Table 3.1) and 
SYBR Green I for detection (Section 3.2.5). 
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4.2.3 Morphological differentiation of the transfected cell lines  
To induce cell differentiation, the stable transfected cells of N-GFRα1a, N-GFRα1b and 
control (N-pIRES) were first seeded in 6-well tissue culture plates (Corning, USA) at a 
cell density of 1 x 104 cells /cm2 in DMEM supplemented with 2 % FBS and 0.8 mg/ml of 
G418 and incubated at 37°C in 5 % CO2, 95 % air humidified atmosphere. After 16 hr of 
incubation, the growth medium was replaced with 2 % FBS/DMEM/G 418 containing 50 
ng/ml of recombinant human GDNF or NTN (Peprotech, USA). The incubation was then 
continued for another 72 hr. Morphological changes of the cells were observed with phase 
contrast microscope (Axiovert 25, Zeiss, Germany) at 10 x 40 magnifications. Cells 
bearing neurites equal or longer than two times the body length were scored positive for 
differentiation. Triplicates were carried out at each of the different conditions and 400 
randomly selected cells from each well were analyzed under the microscope. 
 
4.2.4 Cell proliferation study 
Proliferation profiles of the transfected cell lines, N-GFRα1a, N-GFRα1b and N-pIRES 
cells were measured by two different methods. One was to monitor the increase in the 
absolute cell number using haemocytometer (Section 2.3.3). The second method was 
based on the measurement of BrdU incorporation during DNA synthesis using the cell 
proliferation BiotrakTM ELISA system (Section 2.3.4).  
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4.2.5 Signaling pathway mapping  
4.2.5.1 Cell stimulation by GDNF and NTN 
Four hundred thousand cells (three stably transfected cell lines; N-GFRα1a, N-GFRα1a or 
N-pIRES) in 2 ml of 10% FBS/DMEM with 0.8mg/ml of G418 selection medium were 
first seeded in 6-well tissue culture plate (Corning, USA) and incubated at 37°C in 5 % 
CO2, 95 % air humidified atmosphere for 24 hr. The medium was then replaced by 0.5 % 
FBS/DMEM with 0.8mg/ml G418, a reduced serum medium and the cells were incubated 
for a further 16 hr. For time course study, the cells were then exposed either to 50 ng/ml of 
GDNF or NTN (Peprotech, USA) in a serum free DMEM/G418 media for the indicated 
period of time. For dose response study, the cells were treated with various concentrations 
of either GDNF or NTN in the serum free media for 15 min at 37oC. At the end of 
incubation, the stimulation was terminated by the removal of the media containing the 
stimuli and the cells were then washed once with 1 x PBS. Total cell extract was harvested 
by lysing the cells with 100 µl of 2 % SDS. Positive control was carried out in parallel by 
stimulating cells with 1 M sorbitol (Sigma-Aldrich, USA) in the serum free media. 
 
4.2.5.2 Western blot analysis  
Total protein concentration of the cell extracts in 2 % SDS was quantified by BCA assay 
(Section 2.2.3). Sample of 10 µg of total protein in a volume of 20 µl was loaded, 
electrophoresed in 12 % SDS-PAGE (Section 2.2.1) and transferred onto nitrocellulose 
membrane (Section 2.2.2). Activations of four different signaling pathways were mapped 
by Western blotting and detection (Section 2.2.2) with antibodies against phospho-p44/42 
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MAPK (Thr202/Tyr204), phospho-SAPK/JNK, phospho-AKT or phospho-p38 (Cell 
Signaling, USA), respectively. After detection, the membrane was stripped with RestoreTM 
Western Blot stripping Buffer (Pierce, USA) for 15 min at room temperature, washed with 
large amount of TBST and re-blotted with the respective pan antibodies to verify equal 
loading of all samples. 
 
4.3 Results 
4.3.1  Expression levels of GFRα1a, GFRα1b and c-Ret in transfected 
Neuro2a cells 
The stably transfected cell lines, N-GFRα1a, N-GFRα1b and N-pIRES were established 
under selection of 0.8 mg/ml G 418 and these clones were tested for expressions of the 
two isoforms, GFRα1a and GFRα1b, and endogenous c-Ret by the sequence independent 
real time PCR using specific exon overlapping primers as described in section 3.2.5.5. All 
cDNA samples (Section 4.2.2) were diluted and amplified in parallel with standard 
templates. 
In N-pIRES control cells, the expression levels of both GFRα1a and GFRα1b were at the 
detection limits of the assays (Fig.4.1). In transfected cells (N-GFRα1a and N-GFRα1b), 
the respective receptors were expressed at comparable high levels (Fig.4.1). The 
expression levels of c-Ret were not affected by the transgenes in any of the transfected 
cell-lines as assessed by either real time PCR or Western blot (Fig.4.1 and Fig.4.2). 
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4.3.2 GDNF and NTN induced the differentiation of GFRα1a but not 
GFRα1b transfected cells.  
To directly assess the participation of the spliced isoforms in neuritogenesis of 
neuroblastoma cells, the morphological changes of the stably transfected cell lines, N-
GFRα1a or N-GFRα1b and N-pIRES were monitored after stimulations with specific 
ligands GDNF and NTN (Section 4.2.3). GFRα1a transfected Neuro2a cells (N-GFRα1a) 
demonstrated dramatic morphological changes with extensive branching of the neurites 
when stimulated by NTN or GDNF. However, GFRα1b transfected cells did not show any 
significant changes in morphology when compared to the control cells (N-pIRES) (Fig.4.3 
and Fig.4.4). 90% or more of N-GFRα1b and N-pIRES cells showed rounded 














































































Fig.4.1 Expression levels of GFRα1a, GFRα1b and c-Ret in the transfected cell lines, N-pIRES, N-
GFRα1a and N-GFRα1b respectively. 
The levels of these transcripts were measured by real time PCR using the specific exon overlapping 
primers detected by SYBR Green I. The number of molecules (y-axis, mean ± SD) indicated the 
relative expression levels of GFRα1a (unfilled bars), GFRα1b (filled bars) and c-Ret (hatched bars) 
normalized to 105 molecules of GAPDH expressed in the same cell sample preparation. The 
differences of the expression levels of c-Ret between the three cell lines, and GFRα1a in N-GFRα1a 








Fig.4.3 Percentages of differentiated cells (N-GFRα1a, N-GFRα1b and N-pIRES cells) when induced 
by GDNF (hatched bar) and NTN (filled bar).  
Cells were incubated in 2% FCS/DMEM containing 50 ng/ml of GDNF or NTN for 72 hr. The 
percentages of differentiated cells (y-axis, mean ± S.D.) indicates number of cells differentiated (≥400 
randomly selected cells in triplicate were counted). Cells with neurites, the lengths were at least two 
cell bodies in diameter were considered positive for differentiation. Significant differences in the 
extent of the differentiation of each experimental condition were calculated by comparing to control 
cells N-pIRES, using two-tailed t-test. A value of p<0.05 was considered significant (*p<0.05). Similar 










































Fig.4.2 Expressions of c-Ret in the three
transfected cell lines detected by 
Western blotting. The blot was stripped 
and re-probed with anti-Actin antibody 














Fig.4.4 Morphological differentiation induced by NTN 
Neuro2a transfected cell lines N-GFRα1a, N-GFRα1b and N-pIRES, were plated in 2% FCS/DMEM 
for 16 hr. The cells were then stimulated with 2%FCS/DMEM containing 50 ng/ml of NTN and 





4.3.3 Cell proliferation profiles of GFRα1a and GFRα1b transfected cells 
were similar.  
The effects of GFRα1and GFRα1b on growth rates of the transfected Neuro2a cells were 
determined by cell counting and by measuring the rate of DNA synthesis (Section 4.2.4). 
There was no significant differences in the rates of cell proliferation of either N-GFRα1a 
cells (expressing GFRα1a) or N-GFRα1b cells (expressing GFRα1b) and the control N-
pIRES cells (containing pIRES vector only) grown in 10 % FBS/DMEM or 2 % 
FBS/DMEM (Fig.4.5). Stimulation with either 50 ng/ml of GDNF or NTN did not affect 
cell proliferation in any of the transfected cells up for to 5 days. Furthermore, the rates of 
cell proliferation were similar with the different transfected cells at all doses of GDNF or 













Fig.4.5 Proliferation study of the transfected cells expressing GFRα1a (N-GFRα1a) or GFRα1b (N-
GFRα1b) and the control cells by cell counting (N-pIRES) 
Cells were incubated at four different experimental conditions, (A) in 10 % FBS normal growth 
medium, (B) in 2 % FBS serum reduced growth medium, (C) in 2 % FBS medium containing 50 
ng/ml of NTN, and (D) in 2 % FBS medium containing 50 ng/ml of GDNF, for up to 5 days as 
described in section 4.2.4. The cell number was determined at the indicated period of time by 
Haemocytometer cell count. Values of y-axis (mean ± SEM) represent the mean of triplicate 
experiments. The differences between the growth rates of the three cell lines were not statistically 




















































































































































































































Fig.4.6 Proliferation study by measuring BrdU incorporation. The transfected cells expressing either 
GFRα1a (N-GFRα1a cells ) or GFRα1b (N-GFRα1b cells ) and the control cells (N-pIRES) were 
stimulated with the indicated concentration of GDNF or NTN in the 2 % FBS growth media for either 
24 hr or 54 hr. The incorporation rate of BrdU was measured by ELISA as described in section 4.2.4. 
Values (mean ±S.E.M) of y-axis represent the mean of triplicate experiments. The differences of the 
growth rates between the three cell lines were not statistically significant (p>0.5, paired student t-test 




4.3.4 Kinetic differences in the activation of Erk1/Erk2 signaling pathway 
between the two spliced isoforms 
4.3.4.1 Dose response study  
To investigate the role of the two GFRα1 isoforms in the signaling pathway, a dose 
response study of the transfected Neuro2a cells was first carried out. The cells were 
stimulated with various concentrations of either recombinant GDNF or NTN for 15 min 
(Section 4.2.5.1) and the activation of Erk1/2, JNK, AKT and p38 signaling pathways 
were examined by Western blotting with the specific phosphoepitope antibodies (Section 
4.2.5.2). Stimulation with either GDNF or NTN (10-100 ng/ml) resulted in the significant 
phosphorylation of Erk1/2 in both N-GFRα1a and N-GFRα1b cells, but not in N-pIRES 
control cells (Fig.4.7). Phosphorylation of JNK, AKT and p38 were not significantly 
detected in all the cell lines (data not shown). 
Fig.4.7 Activation of Erk1/2 in the transfected cells stimulated by GDNF or NTN and detected by 
Western blotting. The cells were stimulated in 2 % FBS/DMEM with various concentrations of either 
GDNF or NTN for 15 min. (A) N-GFRα1a and N-GFRα1b cells were stimulated with 0 to 100 ng/ml of 
GDNF or NTN. (B) The control cells (N-pIRES) were stimulated under same conditions with GDNF 
 0   10   25  50  100  S    0  10 25  50  100 S       0  10   25  50  100   S    0   10   25  50 100  S
  Dose 
(ng/ml) 
  GDNF 
 
   NTN 
N-GFRα1a      N-GFRα1b     N-GFRα1a  N-GFRα1b
Pan-Erk1/2 Phospho-Erk1/2
(A) 
0   10   25  50 100  S    0 10 25  50  100  S           0  10  25  50  100   S   0  10   25   50 100 S




or NTN. Sorbital was used as a positive control (S). The blots were probed with phospho-Erk1/2, 
subsequently stripped and re-probed with pan-Erk1/2 to ensure equal loadings of all samples. 
 
4.3.4.2 Time course study 
As the dose response study showed a significant activation of Erk1/2 of the transfected 
cells under the stimulation of GDNF and NTN, a time course study was carried out for the 
transfected cells (Section 4.2.5.1). The stimulation with 50ng/ml of GDNF or NTN 
resulted in the rapid phosphorylation of Erk1/2 in N-GFRα1a and N-GFRα1b cells 
(Fig.4.8A), but not in N-pIRES cells. Both N-GFRα1a and N-GFRα1b cells were equally 
stimulated by GDNF within the tested time period and the phosphorylation of Erk1/2 was 
maximal by the first 15 min (Fig.4.8A). However, a slight but significant difference in the 
kinetics of the phosphorylation of Erk1/2 was observed when N-GFRα1a and N-GFRα1b 
cells were exposed to NTN. Quantitation using ChemiDocTM system (ChemiDocTM MZL, 
Bio-Rad Laboratories, Italy) of intensity of the phosphorylation revealed the maximum 
magnitude of phosphorylation by the first 15 min in both cell lines. The magnitude of the 
















Fig.4.8 Phosphorylation of Erk1/Erk2 stimulated by GDNF and NTN in Neuro2a stably transfected 
cells (N-GFRα1a and N-GFRα1b). The cells were stimulated with 50 ng/ml of recombinant GDNF or 
NTN for the indicated period of time (0-180 min) at 37°C. Sorbitol (S) was used as a positive control 
for the cell stimulations. (A) Phosphorylation of Erk1/2 was detected by Western blotting. The blots 
were stripped and re-probed with pan-Erk1/2 antibodies to show equal amounts of sample loading. 
The experiment was repeated three separate times with similar results. (B) Quantitation of the 
intensity of the phosphorylation of Erk1/2. The degree of phosphorylation is given in arbitrary units. 
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Alternative splicing of pre-mRNA produces functionally diverse proteins from a single 
gene (Modrek et al. 2001). Distinct ligand binding affinities, signaling pathways and 
physiological functions have been observed with different spliced isoforms of SCF 
receptor (Voytyuk et al. 2003), FGF receptor (Sleeman et al. 2001) and VEGF receptors 
(Robinson and Stringer 2001). In the GDNF family, spliced isoforms of GFRα2 (Wong 
and Too 1998) and GFRα4 (Lindahl et al. 2000) have recently been reported. Spliced 
variants of c-RET have shown distinct biochemical and physiological functions in kidney 
development and disease (Lee et al. 2002). This is consistent with the view that the 
combinatorial interactions of the spliced isoforms of GFRα and c-Ret, may contribute to 
the multi-component signaling system to produce the myriad of observed biological 
responses (Airaksinen and Saarma 2002).  
Currently, little is known of the expression levels of the GFRα1 spliced isoforms in human. 
This is the first study to measure the transcriptional expression levels of the two GFRα1 
isoforms in human tissues. The limited differences in nucleotide sequences pose a 
significant challenge for accurate detection and quantification of the two spliced isoforms. 
Previous studies have detected the expressions of GFRα1 in various tissues by PCR, using 
primers that amplify common sequences shared by both isoforms (Gimm et al. 2001; Lee 
et al. 2002). Similarly, all in situ hybridization studies to date have used probes that could 
not distinguish the two isoforms (Burazin and Gundlach 1999; Josephson et al. 2001). One 
approach to detect GFRα1a is to use a specific fluorogenic probe that detects the unique 
sequences of exon 5 and a pair of common primers for amplification (Fig.3.1). But the 
presence of increasing amounts of a related template (GFRα1b) significantly affected the 
quantification of the target gene, GFRα1a (Fig.3.5). This was due to a failure of 
amplifying GFRα1a efficiently when another template, GFRα1b, with highly homologous 
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sequence was present. The use of common primers for amplification and specific 
fluoroprobes for detection of spliced variants has previously been attempted with limited 
success (Kafert et al. 1999). Hence, to achieve high specificity of detection, we have 
designed a specific exon overlapping sense primer and a common antisense primer for 
amplifying the two isoforms. Similar to this approach, others have also reported using 
exon overlapping primers to detect different spliced variants (Vandenbroucke et al. 2001; 
Wellmann et al. 2001). 
The amplification using exon overlapping primers was highly specific and able to 
discriminate the amplifications of the spliced isoforms by greater than 100,000 fold. 
GFRα1b, rather than GFRα1a, was found to be the predominant isoform expressed in all 
the human peripheral tissues examined. In both adult and fetal human liver, the expression 
levels of GFRα1b were much greater than GFRα1a (Fig.10). In adult liver, the expression 
level of c-RET was undetectable. The mismatch between the expression levels of GFRα1 
and c-RET has been observed in rodent liver (Golden et al. 1999) and certain areas of the 
brain, including the cortex (Trupp et al. 1997). It suggests that GFRα1 may associate with 
other signaling molecules or signals through c-RET independent pathway (Pezeshki et al. 
2001). This proposal has been supported by the most recent report that GDNF can also 
signal through the neural cell adhesion molecule N-CAM independent of c-Ret and 
activate Fyn and FAK (Paratcha et al. 2003). In human fetal and adult kidneys, the 
expressions of c-Ret isoforms, GDNF and GFRα1 have been reported (Lee et al. 2002). 
However, the primers used in their study did not distinguish between the two isoforms. In 
this study, we found that the predominant GFRα1 isoform expressed in the human kidney 
is GFRα1b (Fig.10). Hence, the GFRα1b isoform may be responsible for many of the 
presently reported functions. Recently, both GDNF and GFRα1 have been detected in the 
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human testis (Davidoff et al. 2001). The predominant isoform of GFRα1 expressed in the 
adult human testis was GFRα1b (Fig.10), suggesting a major role of this spliced variant in 
the physiology of the testis. Unlike the peripheral organs, the differences in the expression 
levels of the two GFRα1 isoforms in the fetal and adult human brains were less (Fig.10). 
c-Ret expression was comparable to the receptor isoforms in fetal brain and significantly 
higher in the adult human brain.  It is not known if both the isoforms coexist in the same 
cells or that the isoforms have distinct distributions in the central nervous system. 
In order to investigate the functional roles of the two isoforms, Neuro2a cells, expressing 
endogenous RET, transfected with either spliced isoforms of GFRα1 were used for the 
study. The differences of signaling transduction of MAPK/Erk pathway was observed for 
the two isoforms. Despite similar dose-responses patterns of cells transfected with 
GFRα1a or GFRα1b towards GDNF and NTN stimulation, time course study showed that 
the kinetics of phosphorylation of Erk1/2 was stronger and more persistent for the 
GFRα1a transfected cells, compared to GFRα1b transfected cells when NTN was used. 
Although the role of Erk activation in the mitogenic response mediated by GFRα1 is 
unclear, it provides an important piece of evidence that the two isoforms have different 
molecular mechanisms in the signaling transduction, which may contribute to the 
functional diversity of GFRα1 isoforms. Differences in the duration of intracellular 
signaling have long been implicated in dictating appropriate outcomes in diverse 
biological systems and duration of Erk activation is critical for cell signaling decisions 
(Marshall 1995; Murphy et al. 2002). In fibroblasts, sustained activation of Erk for several 
hours correlates with S phase entry, whereas transient Erk activation (20-30 min) does not 
(Weber et al. 1997; Balmanno and Cook 1999). In PC12 cells, sustained activation of Erk 
induces cell differentiation, but not for transient Erk activation (Heasley and Johnson 1992; 
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Nguyen et al. 1993). This is consistent with our cell differentiation study result. When two 
transfected cell lines, N-GFRα1a and N-GFRα1b, were stimulated by NTN, only N-
GFRα1a cells displayed a potent morphological differentiation, but not N-GFRα1b cells. 
Sustained Erk1/2 activation presented in N-GFRα1a cells stimulated by NTN may play a 
critical role for this phenomenon, which needs further investigation.  
GFRα1 was originally identified as a specific receptor for GDNF (Jing et al. 1996), but 
recent studies have shown that GFRα1 can also bind and mediate the neurotrophic effects 
of NTN almost equally well as GDNF in cell lines(Baloh et al. 1997; Creedon et al. 1997; 
Jing et al. 1997). Further more, in vivo and in vitro study of midbrain dopamine neurons, 
which express GFRα1 and not GFRα2, appear to survive equally well with both GDNF 
and NTN (Horger et al. 1998).Only soluble GFRα1, which lacks the GPI linkage to the 
cell membrane displayed a high binding specificity for GDNF over NTN in a cell-free 
system in the absence of c-RET (Klein et al. 1997). Our finding on differential responses 
of the two isoforms under stimulation of NTN suggests that GFRα1a and GFRα1b have 
independent physiological functions. 
It is striking that a stretch of only 5 amino acids in the extracellular region of GFRα1 
receptor could cause such differences in the receptor signaling kinetics and dramatic 
differential response to GDNF family ligands. The real time PCR results showed that 
GFRa1b transcript is the predominant isoform expressed in the periphery in human, and 
therefore it may be the major isoform involved in many of the previously reported 
functions of GFRα1. 
Future studies will focus on the understanding the precise mechanisms of differential 
activation of GFRα1a and GFRα1b involved in the cell differentiation. To achieve this, 
different signaling pathways will be mapped to examine if any other possible differential 
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signaling mechanisms are involved other than Eek1/2. The interaction and formation of 
the receptor complex will also be investigated to find out the preferential signaling partner 
of the two spliced isoforms in terms of signaling through c-Ret, NCAM or other 
molecules as well as their isoforms. To gain an overall profile, and to compare the 
differences and similarities of gene expression and regulation of the two isoforms, 
expression profiling analysis will be carried out. Eventually, we will be able to link all 
these observations to the distinct biochemical and physiological functions associated with 
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Media and Buffers 
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2 × PY (1 liter) 
 16 g bacto-peptone,  
 10 g bacto-yeast extract  
 16 g of NaCl, adjust pH to 7.0 with NaOH  
 Top up to 1 liter with double deionized H2O  
 Store at 4oC.  
 
2 × PY agar plates 




Antibiotic-agar plate was made by adding appropriate amount of antibiotic into 
molten agar media at 55°C. The final concentration of antibiotics added in the 
culture media were as follows: 
 Antibiotics   Final concentration  
 Ampicilin   100 µg/ml   





 0.06M CaCl2.2H2O  
 15%  glycerol 
 10mM PIPES pH 7.0  
 
50×TAE (1 liter) 
 242 g TRIS base 
 57.1 ml glacial acetic acid 
 100 ml 0.5 M EDTA, pH 8.0 
 
TE buffer 
 10 mM Tris HCl, pH7.5 




Diethyl pyrocarbonate (DEPC) was added to deionized H2O at a final 
concentration of 0.1% (v/v) for overnight before autoclaving. 
 
10 x MOPS buffer 
 0.2 M MOPS 
 50 mM Sodium acetate 
 10 mM EDTA, pH 7.0 
 
Western analysis (SDS PAGE) 
 
5 × Tris glycine running buffer (1 liter) 
 125 mM Tris-base  
 1.25 M Glycine  
 0.5 % SDS  
 
 10 % resolving gel 5% stacking gel 
dd H2O 4.0 ml 3.0 ml 
30 % Bis/acrylamide 3.33 ml 1.0 ml 
1.5 M Tris-HCl, pH 8.88 2.5 ml 0 
1.0M Tris-HCl, pH6.8 0 0.75 ml 
10 % SDS 0.1 ml 0.05  ml 
10 % APS 0.05 ml 0.05 ml 
TEMED 0.005 ml 0.005 ml 
Total 10 ml 5 ml 
 
Transfer buffer 
 25 mM Tris-base  
 192 mM Glycine 
 20 % Methanol 
 
5× SDS sample loading buffer 
 3 % β mercaptoethanol 
 3% SDS 
 0.3% bromophenol Blue 
 10% glycerol 
 
Tris-buffered saline (TBS)  
 150 mM NaCl,  
 150 mM Tris-Cl (pH 7.5). 
 
Tris-buffered saline (TBST)  




























Bacteria strain and mammalian cell line 
E. coli host cell 
The strains of Escherichia coli (E. coli) used are described in table II. For long term 
storage of bacteria strains, the bacterial cells were stored at -80oC containing 50% glycerol. 
Working stock was prepared by streaking the glycerol stock onto 2 × PY agar plate with 
appropriate antibiotic selection for overnight growth at 37°C. A single colony was picked 





Application; general cloning work 
Genotype: F-/endA1,hsdR17(rk-mk+), supE44, thi-1, recA1, 




E14-(mcr A), rec A1, end A1, gyr A96, thi-1, hsd R17 (rk-, 
mk+), sup E44, rel A1, D (las-pro AB), [F’, tra D36, pro AB, 
lac1q Z∆ M15] 
Table I. E. coli strains 
 
Mammalian cell line 
Neuro 2a, a mouse neuroblastoma cell line was from American Tissue Culture Collection 
(CCL-131, ATCC). 
For long term storage, Neuro 2a cells at the density of 5 x 106 cell/ml in 20% 







Gene Organization and Sequences 
of GFRα1a and GFRα1b 
 
 GFRα1 Gene Structure: 







    1  2                    3            4    5                 6                      7                 8             9      10             11
Exons: 310bp         286bp            294bp       84bp        15bp        337bp                   110bp          135bp          182bp      54bp     753bp
ATG TAG
Introns:   ∼0.8-1.1 kb        ∼0.8kb      ∼1.15kb    >20kb    ∼1.35kb                  >20kb           >20kb          ∼3.9kb            ∼1.05kb     ∼1.1kb 
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Comparison of Human GFRa1b and GFRa1a sequences 
 
The completed sequences of the ORF of GFRa1a and GFRa1b are presented with the 
positions of start and stop codons (in red). Exon 5 is only present in GFRa1a (in red).  
 
Upper line: Human-GFRα1b (BC014962)  
Lower line: Human-GFRα1a (AF038421)  
 
 
183   CTCCCTCGGCAAGACCCAGCGGCGGCTCGGGATTTTTTTGGGGGGGCGGGGACCAGCCCC 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
486   CTCCCTCGGCAAGACCCAGCGGCGGCTCGGGATTTTTTTGGGGGGGCGGGGACCAGCCCC 
 
243   GCGCCGGCACCATGTTCCTGGCGACCCTGTACTTCGCGCTGCCGCTCTTGGACTTGCTCC 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
546   GCGCCGGCACCATGTTCCTGGCGACCCTGTACTTCGCGCTGCCGCTCTTGGACTTGCTCC 
 
303   TGTCGGCCGAAGTGAGCGGCGGAGACCGCCTGGATTGCGTGAAAGCCAGTGATCAGTGCC 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
606   TGTCGGCCGAAGTGAGCGGCGGAGACCGCCTGGATTGCGTGAAAGCCAGTGATCAGTGCC 
 
363   TGAAGGAGCAGAGCTGCAGCACCAAGTACCGCACGCTAAGGCAGTGCGTGGCGGGCAAGG 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
666   TGAAGGAGCAGAGCTGCAGCACCAAGTACCGCACGCTAAGGCAGTGCGTGGCGGGCAAGG 
 
423   AGACCAACTTCAGCCTGGCATCCGGCCTGGAGGCCAAGGATGAGTGCCGCAGCGCCATGG 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
726   AGACCAACTTCAGCCTGGCATCCGGCCTGGAGGCCAAGGATGAGTGCCGCAGCGCCATGG 
 
483   AGGCCCTGAAGCAGAAGTCGCTCTACAACTGCCGCTGCAAGCGGGGTATGAAGAAGGAGA 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
786   AGGCCCTGAAGCAGAAGTCGCTCTACAACTGCCGCTGCAAGCGGGGTATGAAGAAGGAGA 
 
543   AGAACTGCCTGCGCATTTACTGGAGCATGTACCAGAGCCTGCAGGGAAATGATCTGCTGG 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
846   AGAACTGCCTGCGCATTTACTGGAGCATGTACCAGAGCCTGCAGGGAAATGATCTGCTGG 
 
603   AGGATTCCCCATATGAACCAGTTAACAGCAGATTGTCAGATATATTCCGGGTGGTCCCAT 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
906   AGGATTCCCCATATGAACCAGTTAACAGCAGATTGTCAGATATATTCCGGGTGGTCCCAT 
 
663   TCATATC...............AGTGGAGCACATTCCCAAAGGGAACAACTGCCTGGATG 
      |||||||               |||||||||||||||||||||||||||||||||||||| 
966   TCATATCAGATGTTTTTCAGCAAGTGGAGCACATTCCCAAAGGGAACAACTGCCTGGATG 
   exon5 
708   CAGCGAAGGCCTGCAACCTCGACGACATTTGCAAGAAGTACAGGTCGGCGTACATCACCC 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 




768   CGTGCACCACCAGCGTGTCCAATGATGTCTGCAACCGCCGCAAGTGCCACAAGGCCCTCC 
      |||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||| 
1086  CGTGCACCACCAGCGTGTCCAACGATGTCTGCAACCGCCGCAAGTGCCACAAGGCCCTCC 
 
828   GGCAGTTCTTTGACAAGGTCCCGGCCAAGCACAGCTACGGAATGCTCTTCTGCTCCTGCC 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1146  GGCAGTTCTTTGACAAGGTCCCGGCCAAGCACAGCTACGGAATGCTCTTCTGCTCCTGCC 
 
888   GGGACATCGCCTGCACAGAGCGGAGGCGACAGACCATCGTGCCTGTGTGCTCCTATGAAG 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1206  GGGACATCGCCTGCACAGAGCGGAGGCGACAGACCATCGTGCCTGTGTGCTCCTATGAAG 
 
948   AGAGGGAGAAGCCCAACTGTTTGAATTTGCAGGACTCCTGCAAGACGAATTACATCTGCA 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1266  AGAGGGAGAAGCCCAACTGTTTGAATTTGCAGGACTCCTGCAAGACGAATTACATCTGCA 
 
1008  GATCTCGCCTTGCGGATTTTTTTACCAACTGCCAGCCAGAGTCAAGGTCTGTCAGCAGCT 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1326  GATCTCGCCTTGCGGATTTTTTTACCAACTGCCAGCCAGAGTCAAGGTCTGTCAGCAGCT 
 
1068  GTCTAAAGGAAAACTACGCTGACTGCCTCCTCGCCTACTCGGGGCTTATTGGCACAGTCA 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1386  GTCTAAAGGAAAACTACGCTGACTGCCTCCTCGCCTACTCGGGGCTTATTGGCACAGTCA 
 
1128  TGACCCCCAACTACATAGACTCCAGTAGCCTCAGTGTGGCCCCATGGTGTGACTGCAGCA 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1446  TGACCCCCAACTACATAGACTCCAGTAGCCTCAGTGTGGCCCCATGGTGTGACTGCAGCA 
 
1188  ACAGTGGGAACGACCTAGAAGAGTGCTTGAAATTTTTGAATTTCTTCAAGGACAATACAT 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1506  ACAGTGGGAACGACCTAGAAGAGTGCTTGAAATTTTTGAATTTCTTCAAGGACAATACAT 
 
1248  GTCTTAAAAATGCAATTCAAGCCTTTGGCAATGGCTCCGATGTGACCGTGTGGCAGCCAG 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1566  GTCTTAAAAATGCAATTCAAGCCTTTGGCAATGGCTCCGATGTGACCGTGTGGCAGCCAG 
 
1308  CCTTCCCAGTACAGACCACCACTGCCACTACCACCACTGCCCTCCGGGTTAAGAACAAGC 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1626  CCTTCCCAGTACAGACCACCACTGCCACTACCACCACTGCCCTCCGGGTTAAGAACAAGC 
 
1368  CCCTGGGGCCAGCAGGGTCTGAGAATGAAATTCCCACTCATGTTTTGCCACCGTGTGCAA 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1686  CCCTGGGGCCAGCAGGGTCTGAGAATGAAATTCCCACTCATGTTTTGCCACCGTGTGCAA 
 
1428  ATTTACAGGCACAGAAGCTGAAATCCAATGTGTCGGGCAATACACACCTCTGTATTTCCA 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1746  ATTTACAGGCACAGAAGCTGAAATCCAATGTGTCGGGCAATACACACCTCTGTATTTCCA 
 
1488  ATGGTAATTATGAAAAAGAAGGTCTCGGTGCTTCCAGCCACATAACCACAAAATCAATGG 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1806  ATGGTAATTATGAAAAAGAAGGTCTCGGTGCTTCCAGCCACATAACCACAAAATCAATGG 
 
1548  CTGCTCCTCCAAGCTGTGGTCTGAGCCCACTGCTGGTCCTGGTGGTAACCGCTCTGTCCA 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 




1608  CCCTATTATCTTTAACAGAAACATCATAGCTGCATTAAAAAAATACAATATGGACATGTA 
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
1926  CCCTATTATCTTTAACAGAAACATCATAGCTGCATTAAAAAAATACAATATGGACATGTA 
 
1668  AAAAGACAAAAACCAAA 
      ||||||||||||||||  
1986  AAAAGACAAAAACCAAG 
 
 
 
